EP1385823A1 - Novel guanidino compounds - Google Patents

Novel guanidino compounds

Info

Publication number
EP1385823A1
EP1385823A1 EP02719463A EP02719463A EP1385823A1 EP 1385823 A1 EP1385823 A1 EP 1385823A1 EP 02719463 A EP02719463 A EP 02719463A EP 02719463 A EP02719463 A EP 02719463A EP 1385823 A1 EP1385823 A1 EP 1385823A1
Authority
EP
European Patent Office
Prior art keywords
group
groups
substituted
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP02719463A
Other languages
German (de)
French (fr)
Other versions
EP1385823A4 (en
EP1385823B1 (en
Inventor
Daniel Chu
Rustum S. Boyce
David Duhl
Bryan Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVARTIS VACCINES AND DIAGNOSTICS Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to EP06025693A priority Critical patent/EP1767525A1/en
Publication of EP1385823A1 publication Critical patent/EP1385823A1/en
Publication of EP1385823A4 publication Critical patent/EP1385823A4/en
Application granted granted Critical
Publication of EP1385823B1 publication Critical patent/EP1385823B1/en
Priority to CY20071100208T priority patent/CY1107442T1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/10—Radicals substituted by halogen atoms or nitro radicals

Definitions

  • This invention relates to melanocortin-4 receptor (MC4-R) agonists and methods of their preparation.
  • the invention also relates to methods of treating melanocortin-4 receptor-mediated diseases, such as obesity or diabetes, by activating the melanocortin-4 receptor with compounds provided herein.
  • Melanocortins are peptide products resulting from post- translational processing of pro-opiomelanocortin and are known to have a broad array of physiological activities.
  • the natural melanocortins include the different types of melanocyte stimulating hormone ( ⁇ -MSH, ⁇ -MSH, ⁇ -MSH) and ACTH. Of these, ⁇ -MSH and ACTH are considered to be the main endogenous melanocortins.
  • the melanocortins mediate their effects through melanocortin receptors (MC-R), a subfamily of G-protein coupled receptors. There are at least five different receptor subtypes (MC1-R to MC5-R). MC1-R mediates pigmentation of the hair and skin. MC2-R mediates the effects of ACTH on steroidogenisis in the adrenal gland. MC3-R and MC4-R are predominantly expressed in the brain. MC5-R is considered to have a role in the exocrine gland system.
  • the melanocortin-4 receptor (MC4-R) is a seven-transmembrane receptor.
  • MC4-R may participate in modulating the flow of visual and sensory information, coordinate aspects of somatomotor control, and/or participate in the modulation of autonomic outflow to the heart. Science 1992 257:1248-125. Significantly, inactivation of this receptor by gene targeting has resulted in mice that develop a maturity onset obesity syndrome associated with hyperphagia, hyperinsulinemia, and hyperglycemia. Cell 1997 Jan 10; 88(1): 131-41. MC4-R has also been implicated in other disease states including erectile disorders, cardiovascular disorders, neuronal injuries or disorders, inflammation, fever, cognitive disorders, and sexual behavior disorders. Hadley M.E. and Haskell- Luevano C, The proopiomelanocortin system. Ann N Y Acad Sci, 1999 Oct 20;885:1.
  • agouti protein is normally expressed in the skin and is an antagonist of the cutaneous MC receptor involved in pigmentation, MC1-R. M. M. Ollmann et al., Science, 278:135-138 (1997).
  • agouti protein overexpression of agouti protein in mice leads to a yellow coat color due to antagonism of MC1-R and increased food intake and body weight due to antagonism of MC4-R.
  • Agouti related protein an agouti protein homologue, antagonizes MC4-R but not MC1-R.
  • AGRP Agouti related protein
  • M. Fong et al. Biochem. Biophys. Res. Commun. 237:629-631 (1997).
  • Administration of AGRP in mice increases food intake and causes obesity but does not alter pigmentation.
  • M. Rossi et al. Endocrinology, 139:4428-4431 (1998). Together, this research indicates that MC4-R participates in energy regulation, and therefore, identifies this receptor as a target for a rational drug design for the treatment of obesity.
  • the instant invention provides potent and specific agonists of
  • X and Y are independently selected from the group consisting of
  • n is 1 , 2, or 3;
  • W is selected from the group consisting of
  • Z ⁇ Z 2 , and Z 3 are independently selected from the group consisting of CR 8 and N;
  • R 1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
  • R 2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
  • R 3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 2 and R 3 may join together to form a ring containing at least two N atoms;
  • R 4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 2 and R 4 may join together to form a ring containing at least two N atoms;
  • R 5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 4 and R 5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R 3 and R 5 may join together to form a ring containing at least two N atoms;
  • R 6 and R 7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH 2 , CN, NO 2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
  • R 8 is independently selected from the group consisting of H, CI, I,
  • R 9 and R 10 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups.
  • Compounds provided by the invention further include prodrugs of the compound of formula I, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
  • L is a covalent bond
  • X and Y have the values according to any of the previous embodiments.
  • Z 1 , Z 2 , and Z 3 are all CH, and X, Y, and L have the values according to any of the previous embodiments.
  • At least one of Z 1 , Z 2 , or Z 3 is N, and X,
  • Y, and L have the values according to any of the previous embodiments.
  • X, Y, L, Z Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups.
  • X, Y, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is 2,4-disubstituted phenethyl.
  • X, Y, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
  • X, Y, L, ⁇ Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4- methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4- hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
  • X, Y, L, Z 1 , Z 2 , Z 3 , and R 1 have any of the values of previous embodiments, and R 2 is H.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments, and R 3 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments, and R 3 is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments
  • R 3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2- dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5- dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2- aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3- diaminocyclohexyl, 2,4-
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments
  • R 3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2- dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5- dimethylcyclohexyl, 2,6-dimethylcyclohexyI, 3,4-dimethylcyclohexyl, 3- methylcyclohexyl, 4-methyIcyclohexyl, cyclohex-3-enyl, 3,3,5- trimethylcyclohexyl, 4-f-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbomyl,
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments, and R 5 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
  • X, Y, L, Z Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments, R 4 is H, and R 5 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments
  • R 4 is H
  • R 5 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4- ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4- fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments, and R 4 and R 5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments
  • R 4 and R 5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments, and R 4 and R 5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments, and R 4 and R 5 , together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.
  • A is selected from the group consisting of C or CH;
  • X and Y are independently selected from the group consisting of
  • n is 1 , 2, or 3;
  • W is selected from the group consisting of
  • Z 1 , Z 2 , and Z 3 are independently selected from the group consisting of CR 8 and N;
  • R 1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
  • R 2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
  • R 3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 2 and R 3 may join together to form a ring containing at least two N atoms;
  • R 4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 2 and R 4 may join together to form a ring containing at least two N atoms;
  • R 5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 4 and R 5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R 3 and R 5 may join together to form a ring containing at least two N atoms;
  • R 6 and R 7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH 2 , CN, NO 2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, . cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
  • R 8 is independently selected from the group consisting of H, CI, I,
  • R 9 and R 10 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups.
  • Compounds provided by the invention further include prodrugs of the compound of formula II, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
  • X is N
  • Y is NH
  • A is C
  • the bond between X and A is a double bond.
  • X is NH
  • Y is N
  • A is C
  • the bond between Y and A is a double bond.
  • A is C and the bond between either A and X or between A and Y is a double bond.
  • X, Y, and A have any of the values of previous embodiments, and L is a covalent bond.
  • X, Y, A, and L have any of the values of previous embodiments, and Z 1 , Z 2 , and Z 3 are all CH.
  • X, Y, A, and L have any of the values; of previous embodiments, and at least one of Z 1 , Z 2 , or Z 3 is N.
  • X, Y, A, L, Z Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups.
  • X, Y, A, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is 2,4-disubstituted phenethyl.
  • X, Y, A, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
  • X, Y, A, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4- methylphenethyl, 4-chlorophenethyI, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4- hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , and R 1 have any of the values of previous embodiments, and R 2 is H.
  • X, Y, A, L, Z ⁇ Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments, and R 3 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments, and R 3 is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments
  • R 3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2- dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-diaIkylcyclohexyl, 2,5- dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2- aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3- diaminocyclohexy
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments
  • R 3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2- dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5- dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3- methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5- trimethylcyclohexyl, 4-f-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-is
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 5 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, R 4 is H, and R 5 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments
  • R 4 is H
  • R 5 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4- ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4- fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 4 and R 5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments
  • R 4 and R 5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethyl benzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 4 and R 5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 4 and R 5 , together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.
  • X and Y are independently selected from the group consisting of
  • D is selected from the group consisting of N, and C;
  • W is selected from the group consisting of
  • Z 1 , Z 2 , and Z 3 are independently selected from the group consisting of CR 8 and N;
  • R 1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
  • R 2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
  • R 3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 2 and R 3 may join together to form a ring containing at least two N atoms;
  • R 4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 2 and R 4 may join together to form a ring containing at least two N atoms;
  • R 5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 4 and R 5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R 3 and R 5 may join together to form a ring containing at least two N atoms;
  • R 6 and R 7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH 2 , CN, NO 2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
  • R 8 is independently selected from the group consisting of H, CI, I,
  • R 9 and R 10 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups.
  • Compounds provided by the invention further include prodrugs of the compound of formula III, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
  • X is CH 2
  • D is N.
  • Y is CH 2
  • D is N.
  • D is N.
  • X is N
  • Y is NH
  • D is C
  • the bond between X and D is a double bond.
  • X is NH
  • Y is N
  • D is C
  • the bond between Y and D is a double bond.
  • X, Y, and D have any of the values of previous embodiments, and L is a covalent bond.
  • X, Y, D, and L have any of the values of previous embodiments, and Z 1 , Z 2 , and Z 3 are all CH.
  • X, Y, D, and L have any of the values of previous embodiments, and at least one of Z 1 , Z 2 , or Z 3 is N.
  • X, Y, D, L, z ⁇ Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups.
  • X, Y, D, L, Z Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is 2,4-disubstituted phenethyl.
  • X, Y, D, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
  • X, Y, D, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4- methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4- hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , and R 1 have any of the values of previous embodiments, and R 2 is H.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments, and R 3 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments, and R 3 is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments
  • R 3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-aIkylcyclohexyl, 2,2- dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5- dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2- aminocyclohexyl, 3-aminocycIohexyl, 4-aminocyclohexyl, 2,3- diaminocyclohexyl
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments
  • R 3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2- dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5- dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3- methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5- trimethylcyclohexyl, 4-f-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-is
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 5 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, R 4 is H, and R 5 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments
  • R 4 is H
  • R 5 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4- ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4- fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
  • X, Y, D, L, Z Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 4 and R 5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments
  • R 4 and R 5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 4 and R s , together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 4 and R 5 , together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.
  • composition comprising a compound according to the instant invention and a pharmaceutically acceptable carrier.
  • a method of treating an MC4-R mediated disease comprising administering to a subject in need thereof, a compound or composition of the instant invention.
  • a disease to be treated by those methods of the instant invention is obesity, or type I or type II diabetes.
  • the composition is administered orally, rectally, by subcutaneous injection, by intravenous injection, by intramuscular injection, or by intraperitoneal injection.
  • the instant invention relates to novel classes of small molecule melanocortin-4 receptor (MC4-R) agonists. These compounds can be formulated into compositions and are useful in activating MC4-R, or in the treatment of MC4-R-mediated diseases, such as obesity.
  • MC4-R melanocortin-4 receptor
  • Alkyl groups are straight chain lower alkyl groups having 1 to about 8 carbon atoms, as exemplified by methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl. Alkyl groups also include branched chain isomers of straight chain alkyl groups, including, but not limited to, isopropyl, sec-butyl, t- butyl, isopentyl and so on. Representative substituted alkyl groups may be substituted one or more times with, for example, amino, thio, alkoxy, or halo.
  • Cycloalkyl groups are cyclic alkyl groups such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups, and can include two or more bridgehead carbon atoms to form polycyclic rings (e.g., norbornyl or bicydo[3.1.1]heptyl). Cycloalkyl groups also includes rings that are substituted with straight or branched chain alkyl groups as defined above (e.g., bornyl or 2,6,6-trimethylbicyclo[3.1.1]heptyl).
  • Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6-disubstituted cyclohexyl groups or mono-, di- ortri-substituted norbornyl or cycloheptyl groups, which may be substituted with, for example, alkyl, alkoxy, amino, thio, or halo groups.
  • Alkenyl groups are straight chain, branched or cyclic lower alkyl groups having 2 to about 8 carbon atoms, and further including at least one double bond, as exemplified, for instance, by vinyl, propenyl, 2-butenyl, 3- butenyl, isobutenyl, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl groups among others.
  • Alkynyl groups are straight chain or branched lower alkyl groups having 2 to about 8 carbon atoms, and further including at least one triple bond, as exemplified by groups, including, but not limited to, ethynyl, propynyl, and butynyl groups.
  • Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms.
  • aryl groups include, but are not limited to, phenyl, azulene, heptalene, biphenylene, indacene, fluorene, phenanthrene, triphenylene, pyrene, naphthacene, chrysene, biphenyl, anthracenyl, and naphthenyl groups.
  • aryl groups includes groups containing fused rings, such as fused aromatic-aliphatic ring systems, it does not include aryl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members.
  • substituted aryl groups include groups bonded to one or more carbon atom(s), and/or nitrogen atom(s), in the compounds of formulas I and II.
  • Representative substituted aryl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or benzyl groups, which may be substituted with groups including, but not limited to, amino, alkoxy, alkyl, or halo.
  • Cycloalkyialkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a cycloalkyl group as defined above.
  • Arylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
  • Heterocyclyl groups are nonaromatic ring compounds containing 3 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S.
  • heterocyclyl group includes fused ring species including those comprising fused aromatic and nonaromatic groups. However, the phrase does not include heterocyclyl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members. Rather, these are referred to as "substituted heterocyclyl groups”.
  • Heterocyclyl groups include, but are not limited to, piperazino, morpholino, thiomorpholino, pyrrolidino, piperidino and homopiperazino groups.
  • Representative substituted heterocyclyl groups may be mono-substituted or substituted more than once, such as, but not limited to morphilino or piperazino groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with groups including, but not limited to, amino, alkoxy, alkyl, or halo.
  • Heteroaryl groups are aromatic ring compounds containing 3 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S.
  • Heteroaryl groups include, but are not limited to, groups such as furan, thiophene, pyrrole, isopyrrole, diazole, imidazole, isoimidazole, triazole, dithiole, oxathiole, isoxazole, oxazole, thiazole, isothiazole, oxadiazole, oxatriazole, dioxazole, oxathiazole, pyran, dioxin, pyridine, pyrimidine, pyridazine, pyrazine, triazine, oxazine, isoxazine, oxathiazine, azepin, oxepin, thiepin, diazepine, benzo
  • heteroaryl groups includes fused ring compounds, the phrase does not include heteroaryl groups that have other groups bonded to one of the ring members, such as alkyl groups. Rather, heteroaryl groups with such substitution are referred to as "substituted heterocyclyl groups”. Representative substituted heterocyclyl groups may be substituted one or more times with groups including, but not limited to, amino, alkoxy, alkyl, or halo.
  • Heterocyclylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group as defined above.
  • Heteroarylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above.
  • Aminocarbonyl groups are groups of the formula RR'NC(O)-, wherein R or R' may be the same or different, and each is independently selected from H, or substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl groups, as defined above.
  • substituted refers to a group as defined above in which one or more bonds tb a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms such as, but not limited to, a halogen atom such as F, CI, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, and ester groups; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as in trialkylsilyl groups, dialkylarylsilyl groups
  • Substituted alkyl groups and also substituted cycloalkyl groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom is replaced by a bond to a heteroatom such as oxygen in carbonyl, carboxyl, and ester groups; nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • Substituted cycloalkyl, substituted aryl, substituted heterocyclyl and substituted heteroaryl also include rings and fused ring systems which may be substituted with alkyl groups as defined above.
  • Substituted arylalkyl groups may be substituted on the aryl group, on the alkyl group, or on both the aryl and alkyl groups.
  • the instant invention provides potent and specific agonists of MC4-R that are low molecular weight non-peptide small molecules.
  • n is 1 , 2, or 3;
  • W is selected from the group consisting of
  • Z 1 , Z 2 , and Z 3 are independently selected from the group consisting of CR 8 and N;
  • R 1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
  • ⁇ R 2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
  • R 3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 2 and R 3 may join together to form a ring containing at least two N atoms;
  • R 4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 2 and R 4 may join together to form a ring containing at least two N atoms;
  • R 5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 4 and R 5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R 3 and R 5 may join together to form a ring containing at least two N atoms; [0163] R 6 and R 7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH 2 , CN, NO 2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl,
  • R 8 is independently selected from the group consisting of H, CI, I,
  • R 9 and R 10 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups.
  • Compounds provided by the invention further include prodrugs of the compound of formula I, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
  • L is a covalent bond
  • X and Y have the values according to any of the previous embodiments.
  • Z 1 , Z 2 , and Z 3 are all CH, and X, Y, and L have the values according to any of the previous embodiments. [0172] In another embodiment, at least one of Z Z 2 , or Z 3 is N, and X,
  • Y, and L have the values according to any of the previous embodiments.
  • X, Y, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups.
  • X, Y, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is 2,4-disubstituted phenethyl.
  • X, Y, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
  • X, Y, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4- methylphenethyl, 4-chIorophenethyl, 4-chlorobenzyl, 4-ethyl phenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4- hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
  • X, Y, L, Z Z 2 , Z 3 , and R 1 have any of the values of previous embodiments, and R 2 is H.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments, and R 3 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments, and R 3 is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments
  • R 3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2- dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5- dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2- aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3- diaminocyclohexyl, 2,4-
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments
  • R 3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2- dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5- dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3- methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5- trimethylcyclohexyl, 4-f-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbomyl, 4-iso
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments, and R 5 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments, R 4 is H, and R 5 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments
  • R 4 is H
  • R 5 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4- ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4- fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments, and R 4 and R 5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments
  • R 4 and R 5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
  • X, Y, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments, and R 4 and R 5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.
  • X, Y, L, Z Z 2 , Z 3 , R 1 , R 2 , and R 3 have any of the values of previous embodiments, and R 4 and R 5 , together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.
  • A is selected from the group consisting of C or CH;
  • X and Y are independently selected from the group consisting of
  • n is 1 , 2, or 3;
  • W is selected from the group consisting of
  • Z 1 , Z 2 , and Z 3 are independently selected from the group consisting of CR 8 and N;
  • R 1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
  • R 2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
  • R 3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 2 and R 3 may join together to form a ring containing at least two N atoms;
  • R 4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 2 and R 4 may join together to form a ring containing at least two N atoms;
  • R 5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 4 and R 5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R 3 and R 5 may join together to form a ring containing at least two N atoms;
  • R 6 and R 7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH 2 , CN, NO 2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
  • R 8 is independently selected from the group consisting of H, CI, I,
  • R 9 and R 0 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups.
  • Compounds provided by the invention further include prodrugs of the compound of formula II, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
  • X is N
  • Y is NH
  • A is C
  • the bond between X and A is a double bond.
  • X is NH
  • Y is N
  • A is C
  • the bond between Y and A is a double bond.
  • A is C and the bond between either A and X or between A and Y is a double bond.
  • X, Y, and A have any of the values of previous embodiments, and L is a covalent bond.
  • X, Y, A, and L have any of the values of previous embodiments, and Z 1 , Z 2 , and Z 3 are all CH.
  • X, Y, A, and L have any of the values of previous embodiments, and at least one of Z 1 , Z 2 , or Z 3 is N.
  • X, Y, A, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups.
  • R 1 is 2,4-disubstituted phenethyl.
  • X, Y, A, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
  • X, Y, A, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4- methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4- hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , and R 1 have any of the values of previous embodiments, and R 2 is H.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments, and R 3 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments, and R 3 is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.
  • X, Y, A, L, Z Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments
  • R 3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2- dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-diaIkylcyclohexyl, 2,5- dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2- aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3- diaminocyclohexyl, 2,
  • X, Y, A, L, Z Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments
  • R 3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2- dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5- dimethylcyclohexyl, 2,6-dimethyIcyclohexyl, 3,4-dimethylcyclohexyl, 3- methylcyclohexyl, 4-methylcycIohexyl, cyclohex-3-enyl, 3,3,5- trimethylcyclohexyl, 4- ⁇ -butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbomyl
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R , R 2 and R 3 have any of the values of previous embodiments, and R 5 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, R 4 is H, and R 5 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments
  • R 4 is H
  • R 5 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4- ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4- fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
  • X, Y, A, L, z ⁇ Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 4 and R 5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
  • X, Y, A, L, Z , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments
  • R 4 and R 5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 4 and R 5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.
  • X, Y, A, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 4 and R 5 , together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.
  • X and Y are independently selected from the group consisting of
  • D is selected from the group consisting of N, and C;
  • Y is not N, but may be NH
  • Y is N, then X is not N, but may be NH;
  • W is selected from the group consisting of
  • Z 1 , Z 2 , and Z 3 are independently selected from the group consisting of CR 8 and N;
  • R 1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
  • R 2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
  • R 3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 2 and R 3 may join together to form a ring containing at least two N atoms;
  • R 4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 2 and R 4 may join together to form a ring containing at least two N atoms;
  • R 5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R 4 and R 5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R 3 and R 5 may join together to form a ring containing at least two N atoms;
  • R 6 and R 7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH 2 , CN, NO 2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
  • R 8 is independently selected from the group consisting of H, CI, I,
  • R 9 and R 10 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups.
  • Compounds provided by the invention further include prodrugs of the compound of formula III, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
  • X is CH 2
  • D is N.
  • Y is CH 2
  • D is N.
  • D is N.
  • X is N
  • Y is NH
  • D is C
  • the bond between X and D is a double bond.
  • X is NH
  • Y is N
  • D is C
  • the bond between Y and D is a double bond.
  • X, Y, and D have any of the values of previous embodiments, and L is a covalent bond.
  • X, Y, D, and L have any of the values of previous embodiments, and Z 1 , Z 2 , and Z 3 are all CH.
  • X, Y, D, and L have any of the values of previous embodiments, and at least one of Z 1 , Z 2 , or Z 3 is N.
  • X, Y, D, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups.
  • X, Y, D, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is 2,4-disubstituted phenethyl.
  • X, Y, D, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
  • X, Y, D, L, Z 1 , Z 2 , and Z 3 have any of the values of previous embodiments, and R 1 is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4- methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4- hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , and R 1 have any of the values of previous embodiments, and R 2 is H.
  • X, Y, D, L, z ⁇ Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments, and R 3 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments, and R 3 is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R ⁇ and R 2 have any of the values of previous embodiments
  • R 3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2- dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5- dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2- aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3- diaminocyclohexyl, 2,4-
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , and R 2 have any of the values of previous embodiments
  • R 3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2- dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5- dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3- methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5- trimethylcyclohexyl, 4-f-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbomyl, 4-
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 5 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
  • X, Y, D, , Z Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, R 4 is H, and R 5 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments
  • R 4 is H
  • R 5 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4- ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4- fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
  • X, Y, D, L, Z Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 4 and R 5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
  • X, Y, D, L, Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments
  • R 4 and R 5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
  • X, Y, D, L, Z Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 4 and R 5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.
  • X, Y, D, L, Z Z 2 , Z 3 , R 1 , R 2 and R 3 have any of the values of previous embodiments, and R 4 and R 5 , together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.
  • composition comprising a compound according to the instant invention and a pharmaceutically acceptable carrier.
  • a disease to be treated by those methods of the instant invention is obesity, or type I or type II diabetes.
  • the composition is administered orally, rectally, by subcutaneous injection, by intravenous injection, by intramuscular injection, or by intraperitoneal injection.
  • (CR 6 R 7 )n" are used with respect to X and Y in compounds of formula I, II, and III where n has the value of 1 , 2, or 3.
  • Compounds of formula I will be used to illustrate what these variables mean. In compounds of formula I as shown below
  • n 3 and X or Y is a "(CR 6 R 7 ) n " group
  • the three carbon chain may be substituted where each carbon bears the same R 6 and R 7 substituents although this is not required.
  • X could be a - CH 2 CH(CI)C(CI) 2 - group because R 6 and R 7 may be H and CI.
  • either terminus of the group may be bonded to the N atom in the ring containing the X, Y, and N.
  • L may be a covalent bond.
  • the R 1 group is directly bonded to the N in the ring containing the X and Y in compounds of formula I or is directly bonded to A or D in the ring containing the X and Y in compounds of formulas II and III respectively.
  • Pharmaceutically acceptable salts include a salt with an inorganic base, organic base, inorganic acid, organic acid, or basic or acidic amino acid.
  • the invention includes, for example, alkali metals such as sodium or potassium, alkali earth metals such as calcium and magnesium or aluminum, and ammonia.
  • the invention includes, for example, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine.
  • the instant invention includes, for example, hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid.
  • the instant invention includes, for example, formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and prtoluenesulfonic acid.
  • salts of basic amino acids the instant invention includes, for example, arginine, lysine and omithine.
  • Acidic amino acids include, for example, aspartic acid and glutamic acid.
  • Prodrugs as used in the context of the instant invention, includes those derivatives of the instant compounds which undergo in vivo metabolic biotransformation, by enzymatic or nonenzymatic processes, such as hydrolysis, to form a compound of the invention. Prodrugs can be employed to improve pharmaceutical or biological properties, as for example solubility, melting point, stability and related physicochemical properties, absorption, pharmacodynamics and other delivery-related properties.
  • the invention also includes tautomers of the instant compounds.
  • the instant invention also includes all tautomers of formula I, II, and III.
  • the instant invention also, therefore, includes prodrugs, pharmaceutically acceptable salts, stereoisomers, hydrates, hydrides, or solvates of these tautomers.
  • the instant compounds may exist as one or more stereoisomers.
  • stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers.
  • one stereoisomer may be more active and/or may exhibit beneficial effects in comparison to other stereoisomer(s) or when separated from the other stereoisomer(s).
  • stereoisomers of the instant invention necessarily includes mixtures of stereoisomers, individual stereoisomers, or optically active forms.
  • compositions which may be prepared by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers thereof, with pharmaceutically acceptable carriers, excipients, binders, diluents or the like, to treat or ameliorate a variety of disorders.
  • disorders include, but are not limited to obesity, erectile disorders, cardiovascular disorders, neuronal injuries or disorders, inflammation, fever, cognitive disorders, sexual behavior disorders.
  • a therapeutically effective dose further refers to that amount of one or more compounds of the instant invention sufficient to result in amelioration of symptoms of the disorder.
  • compositions of the instant invention can be manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, emulsifying or levigating processes, among others.
  • the compositions can be in the form of, for example, granules, powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions.
  • the instant compositions can be formulated for various routes of administration, for example, by oral administration, by transmucosal administration, by rectal administration, or subcutaneous administration as well as intrathecal, intravenous, intramuscular, intraperitoneal, intranasal, intraocular or intraventricular injection.
  • the compound or compounds of the instant invention can also be administered in a local rather than a systemic fashion, such as injection as a sustained release formulation.
  • the following dosage forms are given by way of example and should not be construed as limiting the instant invention.
  • powders, suspensions, granules, tablets, pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers thereof, with at least one additive or excipient such as a starch or other additive.
  • Suitable additives or excipients are sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, sorbitol, starch, agar, alginates, chitins, chitosans, pectins, tragacanth gum, gum arabic, gelatins, collagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides, methyl cellulose, hydroxypropylmethyl-cellulose, and/or polyvinylpyrrolidone.
  • oral dosage forms can contain other ingredients to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic acid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating agent, binders, a thickeners, buffers, a sweeteners, flavoring agents or perfuming agents. Additionally, dyestuffs or pigments may be added for identification. Tablets and pills may be further treated with suitable coating materials known in the art.
  • Liquid dosage forms for oral administration may be in the form of pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, slurries and solutions, which may contain an inactive diluent, such as water.
  • Pharmaceutical formulations may be prepared as liquid suspensions or solutions using a sterile liquid, such as, but not limited to, an oil, water, an alcohol, and combinations of these.
  • Pharmaceutically suitable surfactants, suspending agents, emulsifying agents may be added for oral or parenteral administration.
  • suspensions may include oils. Such oils include, but are not limited to, peanut oil, sesame oil, cottonseed oil, corn oil and olive oil.
  • Suspension preparation may also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides.
  • Suspension formulations may include alcohols, such as, but not limited to, ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol.
  • Ethers such as but not limited to, poly(ethyleneglycol), petroleum hydrocarbons such as mineral oil and petrolatum; and water may also be used in suspension formulations.
  • the pharmaceutical formulations may be a spray or aerosol containing and appropriate solvents and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
  • a propellant for an aerosol formulation may include compressed air, nitrogen, carbon dioxide, or a hydrocarbon based low boiling solvent.
  • the compound or compounds of the instant invention are conveniently delivered in the form of an aerosol spray presentation from a nebulizer or the like.
  • Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may be employed as solvents or suspending agents.
  • the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri- glycerides.
  • the pharmaceutical formulation may be a powder suitable for reconstitution with an appropriate solution as described above. Examples of these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates.
  • the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
  • the compounds may be formulated for parenteral administration by injection such as by bolus injection or continuous infusion.
  • a unit dosage form for injection may be in ampoules or in multi-dose containers.
  • the pharmaceutical formulations may be in the form of a suppository, an ointment, an enema, a tablet or a cream for release of compound in the intestines, sigmoid flexure and/or rectum.
  • Rectal suppositories are prepared by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers of the compound, with acceptable vehicles, for example, cocoa butter or polyethylene glycol, which is present in a solid phase at normal storing temperatures, and present in a liquid phase at those temperatures suitable to release a drug inside the body, such as in the rectum. Oils may also be employed in the preparation of formulations of the soft gelatin type and suppositories.
  • suspension formulations which may also contain suspending agents such as pectins, carbomers, methyl cellulose, hydroxypropyl cellulose or carboxymethyl cellulose, as well as buffers and preservatives.
  • suspending agents such as pectins, carbomers, methyl cellulose, hydroxypropyl cellulose or carboxymethyl cellulose, as well as buffers and preservatives.
  • excipients and carriers are generally known to those skilled in the art and are thus included in the instant invention. Such excipients and carriers are described, for example, in "Remingtons Pharmaceutical Sciences” Mack Pub. Co., New Jersey (1991 ), which is incorporated herein by reference.
  • the formulations of the invention may be designed for to be short- acting, fast-releasing, long-acting, and sustained-releasing as described below.
  • the pharmaceutical formulations may also be formulated for controlled release or for slow release.
  • the instant compositions may also comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the pharmaceutical formulations may be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections or as implants such as stents. Such implants may employ known inert materials such as silicones and biodegradable polymers.
  • a therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms. Specific dosages may be adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, diet of the subject, dose intervals, administration routes, excretion rate, and combinations of drugs. Any of the above dosage forms containing effective amounts are well within the bounds of routine experimentation and therefore, well within the scope of the instant invention.
  • a therapeutically effective dose may vary depending upon the route of administration and dosage form.
  • the preferred compound or compounds of the instant invention is a formulation that exhibits a high therapeutic index.
  • the therapeutic index is the dose ratio between toxic and therapeutic effects which can be expressed as the ratio between LD5 0 and ED 50 .
  • the LD 50 is the dose lethal to 50% of the population and the ED 5 o is the dose therapeutically effective in 50% of the population.
  • the LD 50 and ED 50 are determined by standard pharmaceutical procedures in animal cell cultures or experimental animals.
  • the present invention also provides methods of enhancing MC4-R activity in a human or non-human animal.
  • the method comprises administering an effective amount of a compound, or composition, of the instant invention to said mammal or non-human animal.
  • Effective amounts of the compounds of the instant invention include those amounts that activate MC4-R which are detectable, for example, by an assay described below in the illustrative Examples, or any other assay known by those skilled in the art that a detect signal transduction, in a biochemical pathway, through activation of G-protein coupled receptors, for example, by measuring an elevated cAMP level as compared to a control model. Accordingly, "activating" means the ability of a compound to initiate a detectable signal. Effective amounts may also include those amounts which alleviate symptoms of a MC4-R disorder treatable by activating MC4-R.
  • An MC4-R disorder, or MC4-R-mediated disease which may be treated by those methods provided, include any biological disorder or disease in which MC4-R is implicated, or which inhibition of MC4-R potentiates a biochemical pathway that is defective in the disorder or disease state.
  • diseases are obesity, erectile disorders, cardiovascular disorders, neuronal injuries or disorders, inflammation, fever, cognitive disorders, and sexual behavior disorders.
  • the instant invention provides compounds, compositions, and methods effective for reducing energy intake and body weight; reducing serum insulin and glucose levels; alleviating insulin resistance; and reducing serum levels of free fatty acids. Accordingly, the instant invention is particularly effective in treating those disorders or diseases associated with obesity or type II diabetes.
  • Treating within the context of the instant invention, therefore, means an alleviation of symptoms associated with a disorder or disease, or halt of further progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder.
  • successful treatment may include an alleviation of symptoms or halting the progression of the disease, as measured by reduction in body weight, or a reduction in amount of food or energy intake.
  • successful treatment of type I or type II diabetes may include an alleviation of symptoms or halting the progression of the disease, as measured by a decrease in serum glucose or insulin levels in, for example, hyperinsulinemic or hyperglycemic patients.
  • protecting groups in organic synthesis is well known with respect to various groups such as hydroxyl groups, amine groups, and sulfhydryl groups. These and other functionalities may be protected from undesirable reactions with various protecting groups known to those skilled in the art such as those set forth in Protective Groups in Organic Synthesis. Greene, T.W., John Wiley & Sons, New York, NY, (1 st Edition, 1981) which can be added or removed using the procedures set forth therein.
  • Examples of protected hydroxyl groups include, but are not limited to, silyl ethers such as those obtained by reaction of a hydroxyl group with a reagent such as, but not limited to, t-butyldimethyl-chlorosilane, trimethylchlorosilane, triisopropylchlorosilane, triethylchlorosilane; substituted methyl and ethyl ethers such as, but not limited to methoxymethyl ether, methythiomethyl ether, benzyloxymethyl ether, t-butoxymethyl ether, 2-methoxyethoxymethyl ether, tetrahydropyranyl ethers, 1 -ethoxyethyl ether, allyl ether, benzyl ether; esters such as, but not limited to, benzoylformate, formate, acetate, trichloroacetate, and trifluoracetate.
  • a reagent such as, but not
  • Examples of protected amine groups include, but are not limited to, amides such as, formamide, acetamide, trifluoroacetamide, and benzamide; imides, such as phthalimide, and dithiosuccinimide; and others.
  • Examples of protected sulfhydryl groups include, but are not limited to, thioethers such as S-benzyl thioether, and S-4-picolyl thioether; substituted S- methyl derivatives such as hemithio, dithio and aminothio acetals; and others.
  • Figure 1 illustrates a general synthetic route for compounds containing the following core structure:
  • the non-guanidino linked portion of the bicyclic core is functionalized.
  • the condensation of an amine and an anhydride gives an N- substituted phthalimide.
  • the phthalimide nitrogen may be functionalized by displacement of an activated alcohol.
  • the functionalized imide may be reduced to the lactam via a two step process.
  • the primary amine may be activated by treatment with thiophosgene to form the thioisocyanate.
  • Sequential coupling of two amines yields the desired lactam products, which can exist in two tautomeric forms.
  • One skilled in the art would recognize that alternative couplings of amines to thioureas exist, such as the use of a myriad of carbodiimide based coupling reagents or alkylation of the sulfur atom with an alkyl halide prior to addition of an amine.
  • Figure 1
  • bicyclic lactams or bicyclic cyloamido compounds can be generally be functionalized by methods known in the art such as N-alkylation with a variety of electrophiles (see R. Larock, Comprehensive Organic Transformations; VHC Publisher's Inc., 1989).
  • Bicyclic lactams can also be generally functionalized as shown in Figure 4. An amine or its activated equivalent (for example an alkyl aluminum amide) is first coupled with a lactone. The resulting product is then used in a subsequent cyclodehydration reaction (for example a Mitsunobu reaction) to give the functionalized bicyclic core.
  • the guanidino moiety may then be installed as described above.
  • Figure 5 illustrates a general synthetic route for compounds of the invention containing the benzimidazole core structure.
  • An activated acid is first condensed with a diaminonitrophenyl starting material followed by exposure of the resulting product to acidic conditions to provide the benzimidazole core.
  • the nitro moiety is then reduced and converted to the functionalized quanidino substituent as described above.
  • benzoxazole and benzthiazole comprise the bicyclic core.
  • These compounds may be constructed as shown in Figure 6.
  • Commercially available (Aldrich) 6- nitrobenzothiazole may be treated with base and quenched with N- chlorosuccinimide to give the halogenated intermediate.
  • This compound may then be used in a number of metal mediated coupling reactions (for example Heck, Stille, Sonogashira coupling reactions) to functionalize the bicyclic core.
  • the nitro group then serves as the attachment point for the guanidino unit.
  • HPLC System HPLC was run on a Waters 2690 HPLC system.
  • Step 6 Preparation of N- ⁇ 2-[2-(2,4-dichlorophenyl)ethyl]-1 -oxo-2,3- dihydro-1 H-isoindol-5-yl ⁇ -N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]thiourea
  • Examples 24 and 25 can be prepared using the procedures described for Example 23.
  • EC 50 values of test compounds were determined by treating cells expressing MC4-R with test compound and lysing the cells and measuring intercellular cAMP concentration with an Amersham-Pharmacia RPA-559 cAMP Scintillation Proximity Assay (SPA) kit.
  • SPA Amersham-Pharmacia RPA-559 cAMP Scintillation Proximity Assay
  • the following compounds were synthesized and tested according to this assay. The following compounds are merely illustrative and should not be construed as limiting of the instant invention.
  • Compounds having an in vitro potency (as measured by EC 50 value) of less than 3 ⁇ M include:
  • mice In vivo studies are conducted to observe the effect of MCR-4 agonists on energy intake, body weight, hyperinsulinemia, and glucose levels. All studies are conducted with male 9-10 week old ob/ob mice which display early onset of obesity, insulin resistance and diabetes due to leptin deficiency. iice are acclimated in the facility for 1 week before studies and are caged idividually. Vehicle-treated (control) and drug treated mice studies are always un in parallel. In multi-day studies, mice (8-15 per group) are monitored for baseline body weight, fasting levels of glucose, insulin, blood lipids and energy expenditure and then are injected twice daily (9 a.m.
  • Blood glucose and oral glucose tolerance are measured using a glucose monitor (Onetouch sold by Lifescan).
  • Free fatty acids are measured using an nonesterfifed free fatty acids enzymatic assay (Waco Chemicals).
  • Serum Insulin levels are measured by immunoassay (Alpco).
  • mice treated IP with the compounds of the present invention show that mice treated with the compounds of the present invention show a significant body weight reduction compared to mice not treated with the compounds of the present invention.
  • Vehicle treated mice show an increase in blood glucose consistent with the rapid progression of diabetes in this mouse strain, whereas the onset of diabetes is slowed down in mice treated with the compounds of the present invention.
  • Oral glucose tolerance tests are performed. Orally administered glucose quickly elevates blood glucose similar to after eating a meal. Vehicle treated mice show an elevated response to glucose consistent with their diabetic state, whereas mice ⁇ ted with the compounds of the present invention show a very much ⁇ H glucose disposal.
  • mice are fasted overnight and free fatty acid levels are measured the following morning. Vehicle treated mice show elevated free fatty acid levels consistent with their obese state, whereas mice treated with the compounds of the present invention show a dramatic 50% decrease. Serum insulin levels are measured one hour after single IP dosing of compounds of the present invention in overnight fasted ob/ob mice. Mice treated with the compounds of the present invention show a dose dependent decrease relative to vehicle.

Abstract

Compounds having general structure I are provided. X and Y are independently selected from the group consisting of CH 2 , N, NR 9 , C=O, C=S, S=O, SO 2 , S, O, (CR 6 R 7 ) n , C(=O)-(CR 6 R 7 ) n , and C(=S)-(CR 6 R 7 ) n , where n is 1, 2, or 3. W is selected from the group consisting of (1a) and (1b). L is selected from the group consisting of N, O, S=O, SO 2 , C(O), NC(O), NC(S), OC(O), OC(S), C(NR 10 ), C(NOR 10 ), and a covalent bond. Z 1 , Z 2 , and Z 3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (MC-4R) and therefore may have useful properties for controlling diseases related to MC-4R action in humans, such as obesity and type II diabetes.

Description

NOVEL GUANIDINO COMPOUNDS
Cross-References to Related Applications
[0001] This application claims priority to U.S. Provisional Application No.
60/282,847 filed April 9, 2001 , the entire disclosure of which is incorporated herein by reference and for all purposes.
Field of the Invention
[0002] This invention relates to melanocortin-4 receptor (MC4-R) agonists and methods of their preparation. The invention also relates to methods of treating melanocortin-4 receptor-mediated diseases, such as obesity or diabetes, by activating the melanocortin-4 receptor with compounds provided herein.
Background of the Invention
[0003] Melanocortins are peptide products resulting from post- translational processing of pro-opiomelanocortin and are known to have a broad array of physiological activities. The natural melanocortins include the different types of melanocyte stimulating hormone (α-MSH, β-MSH, γ-MSH) and ACTH. Of these, α-MSH and ACTH are considered to be the main endogenous melanocortins.
[0004] The melanocortins mediate their effects through melanocortin receptors (MC-R), a subfamily of G-protein coupled receptors. There are at least five different receptor subtypes (MC1-R to MC5-R). MC1-R mediates pigmentation of the hair and skin. MC2-R mediates the effects of ACTH on steroidogenisis in the adrenal gland. MC3-R and MC4-R are predominantly expressed in the brain. MC5-R is considered to have a role in the exocrine gland system. [0005] The melanocortin-4 receptor (MC4-R) is a seven-transmembrane receptor. MC4-R may participate in modulating the flow of visual and sensory information, coordinate aspects of somatomotor control, and/or participate in the modulation of autonomic outflow to the heart. Science 1992 257:1248-125. Significantly, inactivation of this receptor by gene targeting has resulted in mice that develop a maturity onset obesity syndrome associated with hyperphagia, hyperinsulinemia, and hyperglycemia. Cell 1997 Jan 10; 88(1): 131-41. MC4-R has also been implicated in other disease states including erectile disorders, cardiovascular disorders, neuronal injuries or disorders, inflammation, fever, cognitive disorders, and sexual behavior disorders. Hadley M.E. and Haskell- Luevano C, The proopiomelanocortin system. Ann N Y Acad Sci, 1999 Oct 20;885:1.
[0006] Furthermore, observations in connection with endogenous MCx-R antagonists indicate that MC4-R is implicated in endogenous energy regulation. For example, an agouti protein is normally expressed in the skin and is an antagonist of the cutaneous MC receptor involved in pigmentation, MC1-R. M. M. Ollmann et al., Science, 278:135-138 (1997). However, overexpression of agouti protein in mice leads to a yellow coat color due to antagonism of MC1-R and increased food intake and body weight due to antagonism of MC4-R. L. L. Kiefer et al., Biochemistry, 36: 2084-2090 (1997); D. S. Lu et al., Nature, 371 :799-802 (1994). Agouti related protein (AGRP), an agouti protein homologue, antagonizes MC4-R but not MC1-R. T. M. Fong et al., Biochem. Biophys. Res. Commun. 237:629-631 (1997). Administration of AGRP in mice increases food intake and causes obesity but does not alter pigmentation. M. Rossi et al., Endocrinology, 139:4428-4431 (1998). Together, this research indicates that MC4-R participates in energy regulation, and therefore, identifies this receptor as a target for a rational drug design for the treatment of obesity.
[0007] In connection with MC4-R and its uncovered role in the etiology of obesity and food intake, the prior art has reported compounds or compositions that act as agonists or antagonists of MC4-R. As examples, U.S. Patent No. 6,060,589 describes polypeptides that are capable of modulating signaling activity of melanocortin receptors. Also, U.S. Patent Nos. 6,054,556 and 5,731 ,408 describe families of agonists and antagonists for MC4-R receptors that are lactam heptapeptides having a cyclic structure.
[0008] There is a need to for potent and specific agonists of MC4-R that are low molecular weight non-peptide small molecules. Methods of treating a melanocortin-4 receptor mediated disease, such as obesity, with such non- peptide drugs, are also particularly desirable.
Summary of the Invention
[0009] The instant invention provides potent and specific agonists of
MC4-R that are low molecular weight non-peptide small molecules. Thus, there has been provided, in accordance with one aspect of the invention, a compound of formula I:
I wherein
[0010] X and Y are independently selected from the group consisting of
CH2) N, NR9, C=O, C=S, S=O, SO2, S, O, (CR6R7)n, C(=O)-(CR6R7)n, and
C(=S)-(CR6R7)n;
[0011] n is 1 , 2, or 3;
[0012] W is selected from the group consisting of
[0013] L is selected from the group consisting of N, O, S, S=O, SO2,
C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond;
[0014] Z\ Z2, and Z3 are independently selected from the group consisting of CR8 and N;
[0015] R1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
[0016] R2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
[0017] R3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R3 may join together to form a ring containing at least two N atoms;
[0018] R4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R4 may join together to form a ring containing at least two N atoms;
[0019] R5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R4 and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R3 and R5 may join together to form a ring containing at least two N atoms;
[0020] R6 and R7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
[0021] R8 is independently selected from the group consisting of H, CI, I,
F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; and
[0022] R9 and R10 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups.
[0023] Compounds provided by the invention further include prodrugs of the compound of formula I, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
[0024] In one embodiment, X is CH2 and Y is C=O.
[0025] In another embodiment, X is C=O and Y is CH2.
[0026] In another embodiment, X is C=O and Y is C=O.
[0027] In other embodiments, L is a covalent bond, and X and Y have the values according to any of the previous embodiments.
[0028] In another embodiment, Z1, Z2, and Z3 are all CH, and X, Y, and L have the values according to any of the previous embodiments.
[0029] In another embodiment, at least one of Z1, Z2, or Z3 is N, and X,
Y, and L have the values according to any of the previous embodiments.
[0030] In another embodiment, X, Y, L, Z Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups.
[0031] In another embodiment, X, Y, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is 2,4-disubstituted phenethyl.
[0032] In another embodiment, X, Y, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
[0033] In another embodiment, X, Y, L, ∑ Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4- methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4- hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
[0034] In another embodiment, X, Y, L, Z1, Z2, Z3, and R1 have any of the values of previous embodiments, and R2 is H.
[0035] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
[0036] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.
[0037] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2- dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5- dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2- aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3- diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5- diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2- alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3- dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5- dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2- alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3- dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5- dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2- arylcyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbomyl, and decalinyl groups.
[0038] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2- dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5- dimethylcyclohexyl, 2,6-dimethylcyclohexyI, 3,4-dimethylcyclohexyl, 3- methylcyclohexyl, 4-methyIcyclohexyl, cyclohex-3-enyl, 3,3,5- trimethylcyclohexyl, 4-f-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbomyl, 4-isopropylcyclohexyl, 2,6,6- trimethylbicyclo[3.1.1]heptyl, and 3-methylcycloheptyI.
[0039] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, and R5 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
[0040] In another embodiment, X, Y, L, Z Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, R4 is H, and R5 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
[0041] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, R4 is H, and R5 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4- ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4- fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
[0042] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, and R4 and R5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
[0043] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, and R4 and R5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
[0044] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, and R4 and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.
[0045] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, and R4 and R5, together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.
[0046] There has also been provided, in accordance with another aspect of the invention, a compound of formula II:
wherein
[0047] A is selected from the group consisting of C or CH;
[0048] X and Y are independently selected from the group consisting of
CH2, N, C=O, C=S, (CR6R7)n, S=O, SO2, O, NR9, S, C(=O)-(CR6R7)n, and C(=S)-(CR6R7)n;
[0049] n is 1 , 2, or 3;
[0050] W is selected from the group consisting of
[0051] Z1, Z2, and Z3 are independently selected from the group consisting of CR8 and N;
[0052] L is selected from the group consisting of N, O, S, S=O, SO2,
C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond;
[0053] R1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
[0054] R2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
[0055] R3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R3 may join together to form a ring containing at least two N atoms; [0056] R4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R4 may join together to form a ring containing at least two N atoms;
[0057] R5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R4 and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R3 and R5 may join together to form a ring containing at least two N atoms;
[0058] R6 and R7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, . cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
[0059] R8 is independently selected from the group consisting of H, CI, I,
F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; and
[0060] R9 and R10 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups.
[0061] Compounds provided by the invention further include prodrugs of the compound of formula II, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
[0062] In one embodiment, X is N, Y is NH, A is C, and the bond between X and A is a double bond.
[0063] In another embodiment, X is NH, Y is N, A is C, and the bond between Y and A is a double bond.
[0064] In another embodiment, A is C and the bond between either A and X or between A and Y is a double bond.
[0065] In another embodiment, X, Y, and A have any of the values of previous embodiments, and L is a covalent bond.
[0066] In another embodiment, X, Y, A, and L have any of the values of previous embodiments, and Z1, Z2, and Z3 are all CH.
[0067] In another embodiment, X, Y, A, and L have any of the values; of previous embodiments, and at least one of Z1, Z2, or Z3 is N.
[0068] In another embodiment, X, Y, A, L, Z Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups.
[0069] In another embodiment, X, Y, A, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is 2,4-disubstituted phenethyl.
[0070] In another embodiment, X, Y, A, L, Z1 , Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
[0071] In another embodiment, X, Y, A, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4- methylphenethyl, 4-chlorophenethyI, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4- hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
[0072] In another embodiment, X, Y, A, L, Z1, Z2, Z3, and R1 have any of the values of previous embodiments, and R2 is H.
[0073] In another embodiment, X, Y, A, L, Z\ Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
[0074] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.
[0075] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2- dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-diaIkylcyclohexyl, 2,5- dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2- aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3- diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5- diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2- alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3- dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5- dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2- alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3- dialkylthiocyclohexyl, 2,4-diaIkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5- dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2- arylcyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbomyl, bornyl, norbornyl, and decalinyl groups.
[0076] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2- dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5- dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3- methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5- trimethylcyclohexyl, 4-f-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, 2,6,6- trimethylbicyclo[3.1.1]heptyl, and 3-methylcycloheptyl.
[0077] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R5 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
[0078] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, R4 is H, and R5 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
[0079] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, R4 is H, and R5 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4- ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4- fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
[0080] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4 and R5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups. [0081] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4 and R5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethyl benzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
[0082] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.
[0083] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4 and R5, together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.
[0084] There has also been provided, in accordance with another aspect of the invention, a compound of formula 111:
wherein
[0085] X and Y are independently selected from the group consisting of
CH2, N, C=O, NR9, C=S, S=O, SO2, O, S, (CR6R7)n, C(=O)-(CR6R7)n, and
C(=S)-(CR6R7)n;
[0086] D is selected from the group consisting of N, and C;
[0087] If X is N, then Y is not N, but may be NH; [0088] If Y is N, then X is not N, but may be NH;
[0089] If X is CH2, then Y is not CH2;
[0090] If Y is CH2, then X is not CH2;
[0091] If X is NH, then Y is not NH;
[0092] If Y is NH, then X is not NH;
[0093] L is selected from the group consisting of N, O, S, S=O, SO2, C(0), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond;
[0094] W is selected from the group consisting of
[0095] Z1, Z2, and Z3 are independently selected from the group consisting of CR8 and N;
[0096] R1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
[0097] R2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
[0098] R3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R3 may join together to form a ring containing at least two N atoms; [0099] R4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R4 may join together to form a ring containing at least two N atoms;
[0100] R5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R4 and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R3 and R5 may join together to form a ring containing at least two N atoms;
[0101] R6 and R7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
[0102] R8 is independently selected from the group consisting of H, CI, I,
F, Br, OH, NH2, CN, NO , and substituted and unsubstituted alkoxy, amino,' alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; and
[0103] R9 and R10 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups.
[0104] Compounds provided by the invention further include prodrugs of the compound of formula III, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
[0105] In one embodiment, X is CH2, Y is C=O, and D is N.
[0106] In another embodiment, X is C=O, Y is CH2) and D is N.
[0107] In another embodiment, X is C=O, Y is C=O, and D is N.
[0108] In another embodiment, X is N, Y is NH, D is C, and the bond between X and D is a double bond.
[0109] In another embodiment, X is NH, Y is N, D is C, and the bond between Y and D is a double bond.
[0110] In another embodiment, X, Y, and D have any of the values of previous embodiments, and L is a covalent bond.
[0111] In another embodiment, X, Y, D, and L have any of the values of previous embodiments, and Z1, Z2, and Z3 are all CH.
[0112] In another embodiment, X, Y, D, and L have any of the values of previous embodiments, and at least one of Z1, Z2, or Z3 is N.
[0113] In another embodiment, X, Y, D, L, z\ Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups.
[0114] In another embodiment, X, Y, D, L, Z Z2, and Z3 have any of the values of previous embodiments, and R1 is 2,4-disubstituted phenethyl.
[0115] In another embodiment, X, Y, D, L, Z1 , Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
[0116] In another embodiment, X, Y, D, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4- methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4- hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
[0117] In another embodiment, X, Y, D, L, Z1, Z2, Z3, and R1 have any of the values of previous embodiments, and R2 is H.
[0118] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
[0119] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.
[0120] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-aIkylcyclohexyl, 2,2- dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5- dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2- aminocyclohexyl, 3-aminocycIohexyl, 4-aminocyclohexyl, 2,3- diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5- diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2- alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3- dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5- dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2- alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-aIkylthiocyclohexyl, 2,3- dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5- dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2- arylcyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbomyl, bornyl, norbornyl, and decalinyl groups.
[0121] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2- dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5- dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3- methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5- trimethylcyclohexyl, 4-f-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, 2,6,6- trimethylbicyclo[3.1.1]heptyl, and 3-methylcycloheptyl.
[0122] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R5 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
[0123] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, R4 is H, and R5 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
[0124] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, R4 is H, and R5 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4- ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4- fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
[0125] In another embodiment, X, Y, D, L, Z Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4 and R5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
[0126] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4 and R5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
[0127] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4and Rs, together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.
[0128] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4 and R5, together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.
[0129] There has also been provided, in accordance with another aspect of the invention, a composition comprising a compound according to the instant invention and a pharmaceutically acceptable carrier.
[0130] There has also been provided, in accordance with another aspect of the invention, a method of activating MC4-R, comprising administering to a subject in need thereof, an effective amount of a compound or composition of the instant invention.
[0131] There has also been provided, in accordance with another aspect of the invention, a method of treating an MC4-R mediated disease, comprising administering to a subject in need thereof, a compound or composition of the instant invention. [0132] In one embodiment, a disease to be treated by those methods of the instant invention is obesity, or type I or type II diabetes.
[0133] There has also been provided, in accordance with another aspect of the invention, a method of decreasing blood glucose levels, comprising administering to a subject in need thereof, a compound or composition of the instant invention.
[0134] In various alternative embodiments, the composition is administered orally, rectally, by subcutaneous injection, by intravenous injection, by intramuscular injection, or by intraperitoneal injection.
[0135] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
Detailed Description of the Preferred Embodiment
[0136] The instant invention relates to novel classes of small molecule melanocortin-4 receptor (MC4-R) agonists. These compounds can be formulated into compositions and are useful in activating MC4-R, or in the treatment of MC4-R-mediated diseases, such as obesity.
[0137] The following definitions are used throughout this specification:
[0138] Alkyl groups are straight chain lower alkyl groups having 1 to about 8 carbon atoms, as exemplified by methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl. Alkyl groups also include branched chain isomers of straight chain alkyl groups, including, but not limited to, isopropyl, sec-butyl, t- butyl, isopentyl and so on. Representative substituted alkyl groups may be substituted one or more times with, for example, amino, thio, alkoxy, or halo.
[0139] Cycloalkyl groups are cyclic alkyl groups such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups, and can include two or more bridgehead carbon atoms to form polycyclic rings (e.g., norbornyl or bicydo[3.1.1]heptyl). Cycloalkyl groups also includes rings that are substituted with straight or branched chain alkyl groups as defined above (e.g., bornyl or 2,6,6-trimethylbicyclo[3.1.1]heptyl). Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6-disubstituted cyclohexyl groups or mono-, di- ortri-substituted norbornyl or cycloheptyl groups, which may be substituted with, for example, alkyl, alkoxy, amino, thio, or halo groups.
[0140] Alkenyl groups are straight chain, branched or cyclic lower alkyl groups having 2 to about 8 carbon atoms, and further including at least one double bond, as exemplified, for instance, by vinyl, propenyl, 2-butenyl, 3- butenyl, isobutenyl, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl groups among others.
[0141] Alkynyl groups are straight chain or branched lower alkyl groups having 2 to about 8 carbon atoms, and further including at least one triple bond, as exemplified by groups, including, but not limited to, ethynyl, propynyl, and butynyl groups.
[0142] Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms. Thus aryl groups include, but are not limited to, phenyl, azulene, heptalene, biphenylene, indacene, fluorene, phenanthrene, triphenylene, pyrene, naphthacene, chrysene, biphenyl, anthracenyl, and naphthenyl groups. Although the phrase "aryl groups" includes groups containing fused rings, such as fused aromatic-aliphatic ring systems, it does not include aryl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members. Rather, groups such as tolyl are referred to as substituted aryl groups. The phrase "aryl groups" includes groups bonded to one or more carbon atom(s), and/or nitrogen atom(s), in the compounds of formulas I and II. Representative substituted aryl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or benzyl groups, which may be substituted with groups including, but not limited to, amino, alkoxy, alkyl, or halo.
[0143] Cycloalkyialkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a cycloalkyl group as defined above.
[0144] Arylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
[0145] Heterocyclyl groups are nonaromatic ring compounds containing 3 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S. The phrase "heterocyclyl group" includes fused ring species including those comprising fused aromatic and nonaromatic groups. However, the phrase does not include heterocyclyl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members. Rather, these are referred to as "substituted heterocyclyl groups". Heterocyclyl groups include, but are not limited to, piperazino, morpholino, thiomorpholino, pyrrolidino, piperidino and homopiperazino groups. Representative substituted heterocyclyl groups may be mono-substituted or substituted more than once, such as, but not limited to morphilino or piperazino groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with groups including, but not limited to, amino, alkoxy, alkyl, or halo. [0146] Heteroaryl groups are aromatic ring compounds containing 3 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S. Heteroaryl groups include, but are not limited to, groups such as furan, thiophene, pyrrole, isopyrrole, diazole, imidazole, isoimidazole, triazole, dithiole, oxathiole, isoxazole, oxazole, thiazole, isothiazole, oxadiazole, oxatriazole, dioxazole, oxathiazole, pyran, dioxin, pyridine, pyrimidine, pyridazine, pyrazine, triazine, oxazine, isoxazine, oxathiazine, azepin, oxepin, thiepin, diazepine, benzofuran, and isobenzofuran. Although the phrase "heteroaryl groups" includes fused ring compounds, the phrase does not include heteroaryl groups that have other groups bonded to one of the ring members, such as alkyl groups. Rather, heteroaryl groups with such substitution are referred to as "substituted heterocyclyl groups". Representative substituted heterocyclyl groups may be substituted one or more times with groups including, but not limited to, amino, alkoxy, alkyl, or halo.
[0147] Heterocyclylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group as defined above.
[0148] Heteroarylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above.
[0149] Aminocarbonyl groups are groups of the formula RR'NC(O)-, wherein R or R' may be the same or different, and each is independently selected from H, or substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl groups, as defined above.
[0150] In general, "substituted" refers to a group as defined above in which one or more bonds tb a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms such as, but not limited to, a halogen atom such as F, CI, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, and ester groups; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as in trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups. Substituted alkyl groups and also substituted cycloalkyl groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom is replaced by a bond to a heteroatom such as oxygen in carbonyl, carboxyl, and ester groups; nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
[0151] Substituted cycloalkyl, substituted aryl, substituted heterocyclyl and substituted heteroaryl also include rings and fused ring systems which may be substituted with alkyl groups as defined above. Substituted arylalkyl groups may be substituted on the aryl group, on the alkyl group, or on both the aryl and alkyl groups.
[0152] The instant invention provides potent and specific agonists of MC4-R that are low molecular weight non-peptide small molecules. Thus, there has been provided, in accordance with one aspect of the invention, a compound of formula I:
I wherein [0153] X and Y are independently selected from the group consisting of
CH2, N, NR9, C=O, C=S, S=O, SO2, S, O, (CR6R7)n, C(=O)-(CR6R7)n, and C(=S)-(CR6R7)n;
[0154] n is 1 , 2, or 3;
[0155] W is selected from the group consisting of
[0156] L is selected from the group consisting of N, O, S, S=O, SO2,
C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond;
[0157] Z1, Z2, and Z3 are independently selected from the group consisting of CR8 and N;
[0158] R1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
[0159] ■ R2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
[0160] R3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R3 may join together to form a ring containing at least two N atoms;
[0161] R4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R4 may join together to form a ring containing at least two N atoms;
[0162] R5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R4 and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R3 and R5 may join together to form a ring containing at least two N atoms; [0163] R6 and R7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
[0164] R8 is independently selected from the group consisting of H, CI, I,
F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; and
[0165] R9 and R10 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups.
[0166] Compounds provided by the invention further include prodrugs of the compound of formula I, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
[0167] In one embodiment, X is CH2 and Y is C=0.
[0168] In another embodiment, X is C=O and Y is CH2.
[0169] In another embodiment, X is C=O and Y is C=O.
[0170] In other embodiments, L is a covalent bond, and X and Y have the values according to any of the previous embodiments.
[0171] In another embodiment, Z1, Z2, and Z3 are all CH, and X, Y, and L have the values according to any of the previous embodiments. [0172] In another embodiment, at least one of Z Z2, or Z3 is N, and X,
Y, and L have the values according to any of the previous embodiments.
[0173] In another embodiment, X, Y, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups.
[0174] In another embodiment, X, Y, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is 2,4-disubstituted phenethyl.
[0175] In another embodiment, X, Y, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
[0176] In another embodiment, X, Y, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4- methylphenethyl, 4-chIorophenethyl, 4-chlorobenzyl, 4-ethyl phenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4- hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
[0177] In another embodiment, X, Y, L, Z Z2, Z3, and R1 have any of the values of previous embodiments, and R2 is H.
[0178] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
[0179] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups. [0180] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2- dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5- dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2- aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3- diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5- diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2- alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3- dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5- dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2- alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3- dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5- dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2- arylcyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbornyl, and decalinyl groups.
[0181] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2- dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5- dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3- methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5- trimethylcyclohexyl, 4-f-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbomyl, 4-isopropylcyclohexyl, 2,6,6- trimethylbicyclo[3.1.1]heptyl, and 3-methylcycloheptyl.
[0182] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, and R5 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
[0183] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, R4 is H, and R5 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
[0184] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, R4 is H, and R5 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4- ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4- fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
[0185] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, and R4 and R5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
[0186] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, and R4 and R5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
[0187] In another embodiment, X, Y, L, Z1, Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, and R4and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.
[0188] In another embodiment, X, Y, L, Z Z2, Z3, R1, R2, and R3 have any of the values of previous embodiments, and R4 and R5, together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.
[0189] There has also been provided, in accordance with another aspect of the invention, a compound of formula II:
II wherein [0190] A is selected from the group consisting of C or CH;
[0191] X and Y are independently selected from the group consisting of
CH2, N, C=O, C=S, (CR6R7)n, S=O, SO2) O, NR9, S, C(=O)-(CR6R7)n, and C(=S)-(CR6R7)n;
[0192] n is 1 , 2, or 3;
[0193] W is selected from the group consisting of
[0194] Z1, Z2, and Z3 are independently selected from the group consisting of CR8 and N;
[0195] L is selected from the group consisting of N, O, S, S=O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond; [0196] R1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
[0197] R2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
[0198] R3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R3 may join together to form a ring containing at least two N atoms;
[0199] R4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R4 may join together to form a ring containing at least two N atoms;
[0200] R5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R4 and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R3 and R5 may join together to form a ring containing at least two N atoms;
[0201] R6 and R7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
[0202] R8 is independently selected from the group consisting of H, CI, I,
F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; and
[0203] R9 and R 0 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups.
[0204] Compounds provided by the invention further include prodrugs of the compound of formula II, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
[0205] In one embodiment, X is N, Y is NH, A is C, and the bond between X and A is a double bond.
[0206] In another embodiment, X is NH, Y is N, A is C, and the bond between Y and A is a double bond.
[0207] In another embodiment, A is C and the bond between either A and X or between A and Y is a double bond.
[0208] In another embodiment, X, Y, and A have any of the values of previous embodiments, and L is a covalent bond.
[0209] In another embodiment, X, Y, A, and L have any of the values of previous embodiments, and Z1, Z2, and Z3 are all CH.
[0210] In another embodiment, X, Y, A, and L have any of the values of previous embodiments, and at least one of Z1, Z2, or Z3 is N.
[0211] In another embodiment, X, Y, A, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups. [0212] In another embodiment, X, Y, A, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is 2,4-disubstituted phenethyl.
[0213] In another embodiment, X, Y, A, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
[0214] In another embodiment, X, Y, A, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4- methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4- hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
[0215] In another embodiment, X, Y, A, L, Z1, Z2, Z3, and R1 have any of the values of previous embodiments, and R2 is H.
[0216] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
[0217] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.
[0218] In another embodiment, X, Y, A, L, Z Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2- dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-diaIkylcyclohexyl, 2,5- dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2- aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3- diaminocyclohexyl, 2,4-diaminocycIohexyl, 3,4-diaminocyclohexyl, 2,5- diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2- alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3- dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5- dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2- alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3- dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5- dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2- arylcyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbornyl, and decalinyl groups.
[0219] In another embodiment, X, Y, A, L, Z Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2- dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5- dimethylcyclohexyl, 2,6-dimethyIcyclohexyl, 3,4-dimethylcyclohexyl, 3- methylcyclohexyl, 4-methylcycIohexyl, cyclohex-3-enyl, 3,3,5- trimethylcyclohexyl, 4-^-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbomyl, 4-isopropylcyclohexyl, 2,6,6- trimethylbicyclo[3.1.1]heptyl, and 3-methylcycloheptyl.
[0220] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R , R2 and R3 have any of the values of previous embodiments, and R5 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
[0221] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, R4 is H, and R5 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups. [0222] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, R4 is H, and R5 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4- ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4- fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
[0223] In another embodiment, X, Y, A, L, z\ Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4 and R5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
[0224] In another embodiment, X, Y, A, L, Z , Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4 and R5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
[0225] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.
[0226] In another embodiment, X, Y, A, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4 and R5, together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.
[0227] There has also been provided, in accordance with another aspect of the invention, a compound of formula III:
wherein
[0228] X and Y are independently selected from the group consisting of
CH2, N, C=O, NR9, C=S, S=O, SO2, O, S, (CR6R7)n, C(=O)-(CR6R7)n, and
C(=S)-(CR6R7)n;
[0229] D is selected from the group consisting of N, and C;
[0230] If X is N, then Y is not N, but may be NH;
[0231] If Y is N, then X is not N, but may be NH;
[0232] lfXisCH2,thenYisnotCH2;
[0233] If Y is CH2> then X is not CH2;
[0234] IfXisNH.thenYisnotNH;
[0235] IfYisNH.thenXisnotNH;
[0236] L is selected from the group consisting of N, O, S, S=O, SO2,
C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond;
[0237] W is selected from the group consisting of
[0238] Z1 , Z2, and Z3 are independently selected from the group consisting of CR8 and N;
[0239] R1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
[0240] R2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
[0241] R3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R3 may join together to form a ring containing at least two N atoms;
[0242] R4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R4 may join together to form a ring containing at least two N atoms;
[0243] R5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R4 and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R3 and R5 may join together to form a ring containing at least two N atoms;
[0244] R6 and R7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
[0245] R8 is independently selected from the group consisting of H, CI, I,
F, Br, OH, NH , CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; and
[0246] R9 and R10 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups.
[0247] Compounds provided by the invention further include prodrugs of the compound of formula III, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
[0248] In one embodiment, X is CH2, Y is C=O, and D is N.
[0249] In another embodiment, X is C=O, Y is CH2, and D is N.
[0250] In another embodiment, X is C=O, Y is C=O, and D is N.
[0251] In another embodiment, X is N, Y is NH, D is C, and the bond between X and D is a double bond.
[0252] In another embodiment, X is NH, Y is N, D is C, and the bond between Y and D is a double bond. [0253] In another embodiment, X, Y, and D have any of the values of previous embodiments, and L is a covalent bond.
[0254] In another embodiment, X, Y, D, and L have any of the values of previous embodiments, and Z1, Z2, and Z3 are all CH.
[0255] In another embodiment, X, Y, D, and L have any of the values of previous embodiments, and at least one of Z1, Z2, or Z3 is N.
[0256] In another embodiment, X, Y, D, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups.
[0257] In another embodiment, X, Y, D, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is 2,4-disubstituted phenethyl.
[0258] In another embodiment, X, Y, D, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
[0259] In another embodiment, X, Y, D, L, Z1, Z2, and Z3 have any of the values of previous embodiments, and R1 is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4- methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4- hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
[0260] In another embodiment, X, Y, D, L, Z1, Z2, Z3, and R1 have any of the values of previous embodiments, and R2 is H.
[0261] In another embodiment, X, Y, D, L, z\ Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
[0262] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.
[0263] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R\ and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2- dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5- dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2- aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3- diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5- diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2- alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3- dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5- dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2- alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3- dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5- dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2- arylcyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbornyl, and decalinyl groups.
[0264] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, and R2 have any of the values of previous embodiments, and R3 is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2- dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5- dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3- methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5- trimethylcyclohexyl, 4-f-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbomyl, 4-isopropylcyclohexyl, 2,6,6- trimethylbicyclo[3.1.1]heptyl, and 3-methylcycloheptyl.
[0265] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R5 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups.
[0266] In another embodiment, X, Y, D, , Z Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, R4 is H, and R5 is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
[0267] . In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, R4 is H, and R5 is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4- ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4- fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
[0268] In another embodiment, X, Y, D, L, Z Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4 and R5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
[0269] In another embodiment, X, Y, D, L, Z1, Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4 and R5 may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
[0270] In another embodiment, X, Y, D, L, Z Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.
[0271] In another embodiment, X, Y, D, L, Z Z2, Z3, R1, R2 and R3 have any of the values of previous embodiments, and R4 and R5, together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.
[0272] There has also been provided, in accordance with another aspect of the invention, a composition comprising a compound according to the instant invention and a pharmaceutically acceptable carrier.
[0273] There has also been provided, in accordance with another aspect of the invention, a method of activating MC4-R, comprising administering to a subject in need thereof, an effective amount of a compound or composition of the instant invention.
[0274] There has also been provided, in accordance with another aspect of the invention, a method of treating an MC4-R mediated disease, comprising administering to a subject in need thereof, a compound or composition of the instant invention.
[0275] In one embodiment, a disease to be treated by those methods of the instant invention is obesity, or type I or type II diabetes.
[0276] There has also been provided, in accordance with another aspect of the invention, a method of decreasing blood glucose levels, comprising administering to a subject in need thereof, a compound or composition of the instant invention.
[0277] In various alternative embodiments, the composition is administered orally, rectally, by subcutaneous injection, by intravenous injection, by intramuscular injection, or by intraperitoneal injection. [0278] The variables "(CR6R7)n", "C(=O)-(CR6R7)n", and "C(=S)-
(CR6R7)n" are used with respect to X and Y in compounds of formula I, II, and III where n has the value of 1 , 2, or 3. The variable "(CR6R7)n" has the same meaning in compounds of formula I, II, and III. The same is true with respect to the variables "C(=O)-(CR6R7)n" and "C(=S)-(CR6R7)n". Compounds of formula I will be used to illustrate what these variables mean. In compounds of formula I as shown below
I
X and Y are independently selected from the group consisting of CH2, N, NH, C=O, C=S, S=O, SO2, O, (CR6R7)n, C(=O)-(CR6R7)n, and C(=S)-(CR6R7)n; and n is 1 , 2, or 3 as described above. The variable "(CR6R7)n" indicates that X and/or Y may be a one, two, or three carbon chain with the carbons bearing the R6 and R7 groups. Thus, if X is a three carbon chain (n = 3) and Y is a one carbon chain, the ring bearing the X, Y and N will contain 7 members. It should be noted that where n = 3 and X or Y is a "(CR6R7)n" group, the three carbon chain may be substituted where each carbon bears the same R6 and R7 substituents although this is not required. For example, X could be a - CH2CH(CI)C(CI)2- group because R6 and R7 may be H and CI. Thus, the nomenclature used herein is not meant to restrict each of the carbons to bearing exactly the same substituents as would be the case for n = 3 for an X group such as -CH(CI)-CH(CI)-CH(CI)-. This same feature is true with respect to the variables "C(=O)-(CR6R7)n" and "C(=S)-(CR6R7)n". With respect to the variables "C(=O)-(CR6R7)n" and "C(=S)-(CR6R7)n", X and/or Y may contain from two to four carbon atoms since n = 1 , 2, or 3, and the C=O and C=S groups of these species contains one carbon atoms. With respect to the variables "C(=O)-(CR6R7)n" and "C(=S)-(CR6R7)π", either terminus of the group may be bonded to the N atom in the ring containing the X, Y, and N. Thus, the carbonyl carbon of the C(=O)-(CR6R7)n group may be the carbon directly bonded to the N in the ring, but one of the CR6R7 carbons may alternatively be bonded to the ring N atom. Preferably, however, it is the C=O and C=S carbons of such groups that is bonded to the ring N atoms.
[0279] As described above, in some embodiments L may be a covalent bond. In embodiments where L is a covalent bond, the R1 group is directly bonded to the N in the ring containing the X and Y in compounds of formula I or is directly bonded to A or D in the ring containing the X and Y in compounds of formulas II and III respectively.
[0280] Pharmaceutically acceptable salts include a salt with an inorganic base, organic base, inorganic acid, organic acid, or basic or acidic amino acid. As salts of inorganic bases, the invention includes, for example, alkali metals such as sodium or potassium, alkali earth metals such as calcium and magnesium or aluminum, and ammonia. As salts of organic bases, the invention includes, for example, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine. As salts of inorganic acids, the instant invention includes, for example, hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid. As salts of organic acids, the instant invention includes, for example, formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and prtoluenesulfonic acid. As salts of basic amino acids, the instant invention includes, for example, arginine, lysine and omithine. Acidic amino acids include, for example, aspartic acid and glutamic acid.
[0281] Prodrugs, as used in the context of the instant invention, includes those derivatives of the instant compounds which undergo in vivo metabolic biotransformation, by enzymatic or nonenzymatic processes, such as hydrolysis, to form a compound of the invention. Prodrugs can be employed to improve pharmaceutical or biological properties, as for example solubility, melting point, stability and related physicochemical properties, absorption, pharmacodynamics and other delivery-related properties. [0282] The invention also includes tautomers of the instant compounds.
For example, the instant invention also includes all tautomers of formula I, II, and III.
[0283] The instant invention also, therefore, includes prodrugs, pharmaceutically acceptable salts, stereoisomers, hydrates, hydrides, or solvates of these tautomers.
[0284] The instant compounds may exist as one or more stereoisomers.
The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. In some cases, one stereoisomer may be more active and/or may exhibit beneficial effects in comparison to other stereoisomer(s) or when separated from the other stereoisomer(s). However, it is well within the skill of the ordinary artisan to separate, and/or to selectively prepare said stereoisomers. Accordingly, "stereoisomers" of the instant invention necessarily includes mixtures of stereoisomers, individual stereoisomers, or optically active forms.
[0285] The instant invention also provides for compositions which may be prepared by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers thereof, with pharmaceutically acceptable carriers, excipients, binders, diluents or the like, to treat or ameliorate a variety of disorders. Examples of such disorders include, but are not limited to obesity, erectile disorders, cardiovascular disorders, neuronal injuries or disorders, inflammation, fever, cognitive disorders, sexual behavior disorders. A therapeutically effective dose further refers to that amount of one or more compounds of the instant invention sufficient to result in amelioration of symptoms of the disorder. The pharmaceutical compositions of the instant invention can be manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, emulsifying or levigating processes, among others. The compositions can be in the form of, for example, granules, powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions. The instant compositions can be formulated for various routes of administration, for example, by oral administration, by transmucosal administration, by rectal administration, or subcutaneous administration as well as intrathecal, intravenous, intramuscular, intraperitoneal, intranasal, intraocular or intraventricular injection. The compound or compounds of the instant invention can also be administered in a local rather than a systemic fashion, such as injection as a sustained release formulation. The following dosage forms are given by way of example and should not be construed as limiting the instant invention.
[0286] For oral, buccal, and sublingual administration, powders, suspensions, granules, tablets, pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers thereof, with at least one additive or excipient such as a starch or other additive. Suitable additives or excipients are sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, sorbitol, starch, agar, alginates, chitins, chitosans, pectins, tragacanth gum, gum arabic, gelatins, collagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides, methyl cellulose, hydroxypropylmethyl-cellulose, and/or polyvinylpyrrolidone. Optionally, oral dosage forms can contain other ingredients to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic acid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating agent, binders, a thickeners, buffers, a sweeteners, flavoring agents or perfuming agents. Additionally, dyestuffs or pigments may be added for identification. Tablets and pills may be further treated with suitable coating materials known in the art.
[0287] Liquid dosage forms for oral administration may be in the form of pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, slurries and solutions, which may contain an inactive diluent, such as water. Pharmaceutical formulations may be prepared as liquid suspensions or solutions using a sterile liquid, such as, but not limited to, an oil, water, an alcohol, and combinations of these. Pharmaceutically suitable surfactants, suspending agents, emulsifying agents, may be added for oral or parenteral administration. [0288] As noted above, suspensions may include oils. Such oils include, but are not limited to, peanut oil, sesame oil, cottonseed oil, corn oil and olive oil. Suspension preparation may also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides. Suspension formulations may include alcohols, such as, but not limited to, ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol. Ethers, such as but not limited to, poly(ethyleneglycol), petroleum hydrocarbons such as mineral oil and petrolatum; and water may also be used in suspension formulations.
[0289] For nasal administration, the pharmaceutical formulations may be a spray or aerosol containing and appropriate solvents and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability modifiers and combinations of these. A propellant for an aerosol formulation may include compressed air, nitrogen, carbon dioxide, or a hydrocarbon based low boiling solvent. The compound or compounds of the instant invention are conveniently delivered in the form of an aerosol spray presentation from a nebulizer or the like.
[0290] Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may be employed as solvents or suspending agents. Preferably, the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri- glycerides.
[0291] For injection, the pharmaceutical formulation may be a powder suitable for reconstitution with an appropriate solution as described above. Examples of these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates. For injection, the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these. The compounds may be formulated for parenteral administration by injection such as by bolus injection or continuous infusion. A unit dosage form for injection may be in ampoules or in multi-dose containers.
[0292] For rectal administration, the pharmaceutical formulations may be in the form of a suppository, an ointment, an enema, a tablet or a cream for release of compound in the intestines, sigmoid flexure and/or rectum. Rectal suppositories are prepared by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers of the compound, with acceptable vehicles, for example, cocoa butter or polyethylene glycol, which is present in a solid phase at normal storing temperatures, and present in a liquid phase at those temperatures suitable to release a drug inside the body, such as in the rectum. Oils may also be employed in the preparation of formulations of the soft gelatin type and suppositories. Water, saline, aqueous dextrose and related sugar solutions, and glycerols may be employed in the preparation of suspension formulations which may also contain suspending agents such as pectins, carbomers, methyl cellulose, hydroxypropyl cellulose or carboxymethyl cellulose, as well as buffers and preservatives.
[0293] Besides those representative dosage forms described above, pharmaceutically acceptable excipients and carriers are generally known to those skilled in the art and are thus included in the instant invention. Such excipients and carriers are described, for example, in "Remingtons Pharmaceutical Sciences" Mack Pub. Co., New Jersey (1991 ), which is incorporated herein by reference.
[0294] The formulations of the invention may be designed for to be short- acting, fast-releasing, long-acting, and sustained-releasing as described below. Thus, the pharmaceutical formulations may also be formulated for controlled release or for slow release. [0295] The instant compositions may also comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the pharmaceutical formulations may be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections or as implants such as stents. Such implants may employ known inert materials such as silicones and biodegradable polymers.
[0296] A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms. Specific dosages may be adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, diet of the subject, dose intervals, administration routes, excretion rate, and combinations of drugs. Any of the above dosage forms containing effective amounts are well within the bounds of routine experimentation and therefore, well within the scope of the instant invention. A therapeutically effective dose may vary depending upon the route of administration and dosage form. The preferred compound or compounds of the instant invention is a formulation that exhibits a high therapeutic index. The therapeutic index is the dose ratio between toxic and therapeutic effects which can be expressed as the ratio between LD50 and ED50. The LD50 is the dose lethal to 50% of the population and the ED5o is the dose therapeutically effective in 50% of the population. The LD50 and ED50 are determined by standard pharmaceutical procedures in animal cell cultures or experimental animals.
[0297] The present invention also provides methods of enhancing MC4-R activity in a human or non-human animal. The method comprises administering an effective amount of a compound, or composition, of the instant invention to said mammal or non-human animal. Effective amounts of the compounds of the instant invention include those amounts that activate MC4-R which are detectable, for example, by an assay described below in the illustrative Examples, or any other assay known by those skilled in the art that a detect signal transduction, in a biochemical pathway, through activation of G-protein coupled receptors, for example, by measuring an elevated cAMP level as compared to a control model. Accordingly, "activating" means the ability of a compound to initiate a detectable signal. Effective amounts may also include those amounts which alleviate symptoms of a MC4-R disorder treatable by activating MC4-R.
[0298] An MC4-R disorder, or MC4-R-mediated disease, which may be treated by those methods provided, include any biological disorder or disease in which MC4-R is implicated, or which inhibition of MC4-R potentiates a biochemical pathway that is defective in the disorder or disease state. Examples of such diseases are obesity, erectile disorders, cardiovascular disorders, neuronal injuries or disorders, inflammation, fever, cognitive disorders, and sexual behavior disorders. In a preferred embodiment, the instant invention provides compounds, compositions, and methods effective for reducing energy intake and body weight; reducing serum insulin and glucose levels; alleviating insulin resistance; and reducing serum levels of free fatty acids. Accordingly, the instant invention is particularly effective in treating those disorders or diseases associated with obesity or type II diabetes.
[0299] "Treating" within the context of the instant invention, therefore, means an alleviation of symptoms associated with a disorder or disease, or halt of further progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder. For example, within the context of obesity, successful treatment may include an alleviation of symptoms or halting the progression of the disease, as measured by reduction in body weight, or a reduction in amount of food or energy intake. In this same vein, successful treatment of type I or type II diabetes may include an alleviation of symptoms or halting the progression of the disease, as measured by a decrease in serum glucose or insulin levels in, for example, hyperinsulinemic or hyperglycemic patients.
Compound Preparation
[0300] Many of the described specific synthetic transformation steps are familiar to those skilled in the art and their procedures are either described or referenced in common texts such as in March Advanced Organic Chemistry 3rd ed. (Wiley, 1985), Carey and Sundberg Advanced Organic Chemistry A and B 3rd ed. (Plenum Press, 1990), and Vogel's Textbook of Practical Organic Chemistry 5th ed. (Longman, 1989). Implicit in the synthetic transformations are various techniques for purification such as silica gel chromatography, crystallizations, and distillations. These steps may be necessary for isolating the desired product, regioisomer, enantiomer, or diastereomer from a reaction product mixture. Multistep syntheses may also involve the use of protecting groups to address issues of chemo and regioselectivity that cannot otherwise be satisfactorily resolved with respect to chemical purity or yield.
[0301] The use of protecting groups in organic synthesis is well known with respect to various groups such as hydroxyl groups, amine groups, and sulfhydryl groups. These and other functionalities may be protected from undesirable reactions with various protecting groups known to those skilled in the art such as those set forth in Protective Groups in Organic Synthesis. Greene, T.W., John Wiley & Sons, New York, NY, (1st Edition, 1981) which can be added or removed using the procedures set forth therein. Examples of protected hydroxyl groups include, but are not limited to, silyl ethers such as those obtained by reaction of a hydroxyl group with a reagent such as, but not limited to, t-butyldimethyl-chlorosilane, trimethylchlorosilane, triisopropylchlorosilane, triethylchlorosilane; substituted methyl and ethyl ethers such as, but not limited to methoxymethyl ether, methythiomethyl ether, benzyloxymethyl ether, t-butoxymethyl ether, 2-methoxyethoxymethyl ether, tetrahydropyranyl ethers, 1 -ethoxyethyl ether, allyl ether, benzyl ether; esters such as, but not limited to, benzoylformate, formate, acetate, trichloroacetate, and trifluoracetate. Examples of protected amine groups include, but are not limited to, amides such as, formamide, acetamide, trifluoroacetamide, and benzamide; imides, such as phthalimide, and dithiosuccinimide; and others. Examples of protected sulfhydryl groups include, but are not limited to, thioethers such as S-benzyl thioether, and S-4-picolyl thioether; substituted S- methyl derivatives such as hemithio, dithio and aminothio acetals; and others. [0302] Figure 1 illustrates a general synthetic route for compounds containing the following core structure:
[0303] In the first part of the synthesis the non-guanidino linked portion of the bicyclic core is functionalized. In one embodiment of the method of the invention, the condensation of an amine and an anhydride gives an N- substituted phthalimide. Alternatively, if a phthalimide is used as the starting material, the phthalimide nitrogen may be functionalized by displacement of an activated alcohol. These transformations allow access to a wide range of N- substituted intermediates by varying the type of R-|OH or R1NH2 inputs. It can further be appreciated that use of the appropriate starting materials for the bicyclic core can also provide, for example, compounds of the invention containing a nitrogen atom in the aromatic ring to which the guanidino moiety is attached.
[0304] In the next phase of the synthetic route, the functionalized imide may be reduced to the lactam via a two step process. After separation of the desired lactam regioisomer, the primary amine may be activated by treatment with thiophosgene to form the thioisocyanate. Sequential coupling of two amines yields the desired lactam products, which can exist in two tautomeric forms. One skilled in the art would recognize that alternative couplings of amines to thioureas exist, such as the use of a myriad of carbodiimide based coupling reagents or alkylation of the sulfur atom with an alkyl halide prior to addition of an amine. Figure 1
[0305] Use of the other regioisomer obtained from the reduction step would lead to the regioisomeric lactam and its tautomer shown in Figure 2 below.
Figure 2
[0306] Furthermore, the reduction steps in Figure 1 can be omitted in its entirety and the reaction scheme can be carried through to give the guanidino imide and its tautomer shown in Figure 3 as products. Conversely, both carbonyl groups can be fully reduced to give the tetrahydro analogs. Figure 3
[0307] Additional structural variations within the non-guanidino linked portion of the bicyclic core itself can be achieved by starting with, for example, bicyclic lactams or bicyclic cyloamido compounds. These scaffolds can be generally be functionalized by methods known in the art such as N-alkylation with a variety of electrophiles (see R. Larock, Comprehensive Organic Transformations; VHC Publisher's Inc., 1989). Bicyclic lactams can also be generally functionalized as shown in Figure 4. An amine or its activated equivalent (for example an alkyl aluminum amide) is first coupled with a lactone. The resulting product is then used in a subsequent cyclodehydration reaction (for example a Mitsunobu reaction) to give the functionalized bicyclic core. The guanidino moiety may then be installed as described above.
Figure 4
couple
[0308] Figure 5 illustrates a general synthetic route for compounds of the invention containing the benzimidazole core structure. An activated acid is first condensed with a diaminonitrophenyl starting material followed by exposure of the resulting product to acidic conditions to provide the benzimidazole core. The nitro moiety is then reduced and converted to the functionalized quanidino substituent as described above.
Figure 5
[0309] In another embodiment of the invention, benzoxazole and benzthiazole comprise the bicyclic core. These compounds may be constructed as shown in Figure 6. Commercially available (Aldrich) 6- nitrobenzothiazole may be treated with base and quenched with N- chlorosuccinimide to give the halogenated intermediate. This compound may then be used in a number of metal mediated coupling reactions (for example Heck, Stille, Sonogashira coupling reactions) to functionalize the bicyclic core. The nitro group then serves as the attachment point for the guanidino unit.
Figure 6
[0310] The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention. EXAMPLES
[0311] Compounds were named using the ACD/Name v. 4.53.
[0312] The following abbreviations are used throughout the Examples:
eq equivalent
DIAD diisopropylazodicarboxylate DIBAL-H diisobutlyaluminum hydride
EDC 1 -ethyl-3-(3'-dimethylaminopropyl)-carbodiimide hydrochloride
EtOAc ethylacetate
THF tetrahydrofuran
TFA trifluoroacetic acid Analytical Methodology
[0313] HPLC System: HPLC was run on a Waters 2690 HPLC system.
column = Reliasil 50 x 4.6mm (5μm pore size) method: (note: all solvents include 0.1 % TFA) time flow rate %water %
(minutes) (mL/min) in it. 2 95 5
15 2 20 80
15.5 2 0 100
17.5 2 0 100
18.5 2 95 5
Model HPLC = (Waters 2690 Separations Module) detector = (Waters 996 photodiode array detector)
LCMS were run on HP Series 1100 LCMS system HP LCMS (1100 series) HP MSD (1100 series) time flow rate %A* %ϊ
(minutes) (mL/min)
0 0.8 95 5
.2 0.8 95 5
3.7 0.8 5 95
3.85 0.8 95 5
5 0.8 95 5
*solvent A = (water + 0.05% TFA) and solvent B = (Acetonitrile + 0.05% TFA) column temp = 30° C column = (brand = Eclipse XDB) 50 x 2mm (5μm) (C18) MS Methodology
MWT: 150-800 CV: 20 lonization: ESP+ i. Data: Centroid Repeat: 1
Scan Time: 2 seconds
Example 1
[0314] Preparation of (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1-oxo-2,3- dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide
Step 1. Preparation of 2-[2-(2,4-dichlorophenyl)ethyl]-5-nitro-1H- isoindole-1 ,3(2H)-dione
[0315] 2-(2,4-dichlorophenyl)ethanamine was suspended in toluene with
4-nitrophthalic anhydride (1 eq) and heated to 150°C. After 2 hours, the reaction was cooled and checked for completion by LC/MS. The solvent was then removed in vacuo and the resulting product was taken on to the next step without further purification. Rt 3.36 minutes (HP LCMS), LC/MS m/z 365.1 (MH+). Step 2. Preparation of 5-amino-2-[2-(2,4-dichlorophenyl)ethyl]-1W- isoindole-1 ,3(2H)-dione
[0316] The product of the previous step was taken up in ethanol (or methanol) and purged with dry nitrogen. To this solution was introduced activated Pd/C (10% w/w, 0.1 eq) and the mixture was hydrogenated for about 30 minutes or until complete by LC/MS. The mixture was then filtered through celite, concentrated in vacuo, and taken on to the next step. Rt 2.95 minutes (HP LCMS), LC/MS m/z 335.0 (MH+).
Step 3. Preparation of 5-amino-2-[2-(2,4-dichlorophenyl)ethyl]-3- hydroxyisoindolin-1 -one
[0317] To a CH2CI2 solution of the phthalimide was added dropwise
DIBAL-H (3 eq, 1.0 M solution in CH2CI2) at room temperature with good stirring. After stirring for one hour, the reaction was diluted with ether, NaF (12 eq), and distilled water (9 eq) and stirred for an additional hour. The reaction mixture was then filtered through celite to remove the aluminum precipitants. After washing the celite with additional CH2CI2, the filtrate was then concentrated in vacuo to give a crude product (mixture of regioisomers) was then used in the following step without further purification. Rt 2.09 minutes (HP LCMS) and 2.23 minutes (HP LCMS), LC/MS m/z 337.2 (MH+).
Step 4. Preparation of 5-amino-2-[2-(2,4- dichlorophenyl)ethyl]isoindolin-1 -one
[0318] To a CH2CI2 (0.1 M solution) of the crude product from the previous step was added dropwise triflouroacetic acid (6.0 eq) followed immediately by dropwise addition of triethylsilane (2.9 eq). After stirring for an additional 15 minutes, the mixture was concentrated in vacuo. The crude product of two regioisomeric lactams was then dissolved in acetonitrile and purified via reverse phase (C18) prep HPLC. The fractions for the desired regioisomeric lactam product (later retention time) were collected, frozen, and lyophilized. Rt 7.24minutes, LC/MS m/z 321.1 (MH+). Step 5. Preparation of 2-[2-(2,4-dichlorophenyl)ethyl]-5- isothiocyanato-isoindolin-1 -one
[0319] To a 0.5 M solution of the amine in acetone (0°C ice bath) was added thiophosgene (3 eq) dropwise. After 30 minutes, the reaction mixture was allowed to warm to room temperature. After two hours, the reaction mixture was concentrated in vacuo to remove solvent and excess thiophosgene. The crude isothiocyanate product was then used in the next step without further purification. Rt 3.43 minutes (HP LCMS), LC/MS m/z 363.1 (MH+).
Step 6. Preparation of N-{2-[2-(2,4-dichlorophenyl)ethyl]-1 -oxo-2,3- dihydro-1 H-isoindol-5-yl}-N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]thiourea
[0320] To a solution of the crude isothiocyanate in dry acetonitrile (0.5 M solution) was added (+)-isopinocampheyl amine (1.5 eq). After stirring overnight, the reaction mixture was concentrated in vacuo and the thiourea product was dissolved in CH2CI2 and purified via flash chromatography (1 :1
Hexanes:EtOAc). Fractions containing the thiourea product were concentrated in vacuo and dried to yield a creamish white colored solid. Rt 14.53 minutes, LC/MS m/z 516.4 (MH+).
Step 7. Preparation of (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1 -oxo- 2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-
2,6,6-trimethyIbicyclo[3.1.1]hept-3-yl]piperazine-1 - carboximidamide
[0321] To a solution of the thiourea in THF (dry, 0.5 M) in a dry vial was added (S)-(+)-2-methylpiperazine (3 eq) and EDC (3 eq). The vial was capped tightly and heated to 80°C for approximately 2 hours. The mixture was then allowed to cool to room temperature and concentrated in vacuo. The reaction mixture was dissolved in DMSO along with TFA (1 eq) and purified by prep HPLC. The pure fractions were collected, frozen, and dried via lyopholization to give the product as a white solid. Rt 8.36 minutes, LC/MS m/z 582.5 (MH+).
Example 2
[0322] Preparation of (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1 ,3-dioxo-
2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1 ]hept-3-yl]piperazine-1 -carboximidamide
Step 1. Preparation of 2-[2-(2,4-dichlorophenyl)ethyl]-5-nitro-1 H- isoindole-1 ,3(2W)-dione
[0323] 2-(2,4-dichlorophenyl)ethanamine was suspended in toluene with
4-nitrophthalic anhydride (1 eq) and heated to 150°C. After 2 hours, the reaction was cooled and checked for completion by LC/MS. The solvent was then removed in vacuo and the resulting product was taken on to the next step without further purification. Rt3.91 minutes, LC/MS m/z 365.1 (MH+).
Step 2. Preparation of 5-amino-2-[2-(2,4-dichlorophenyl)ethyl]-1 H- isoindole-1 ,3(2r/)-dione
[0324] The product of the previous step was taken up in ethanol (or methanol) and purged with dry nitrogen. To this solution was introduced activated Pd/C (10% w/w, 0.1 eq) and the mixture was hydrogenated for about 30 minutes or until complete by LC/MS. The mixture was then filtered through celite, concentrated in vacuo, and taken on to the next step. Rt 2.96 minutes (HP LCMS), LC/MS m/z 335.1 (MH+).
Step 3. Preparation of 2-[2-(2,4-dichlorophenyl)ethyl]-5- isothiocyanatoiso-1 H-isoindole-1 ,3(2H)dione
[0325] To a 0.5 M solution of the amine in acetone (0°C ice bath) was added thiophosgene (3 eq) dropwise. After 30 minutes, the reaction mixture was allowed to warm to room temperature. After two hours, the reaction mixture was concentrated in vacuo to remove solvent and excess thiophosgene. The crude isothiocyanate product was then used in the next step without further purification. Rt 3.75 minutes (HP LCMS), LC/MS m/z 377.0 (MH+).
Step 4, Preparation of N-{2-[2-(2,4-dichlorophenyl)ethyl]-1 ,3-dioxo-
2,3-dihydro-1 H-isoindol-δ-yty-N'-KI S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]thiourea
[0326] To a solution of the crude isothiocyanate in dry acetonitrile (0.5 M solution) was added (+)-isopinocampheyl amine (1.5 eq). After stirring overnight, the reaction mixture was concentrated in vacuo and the thiourea product was dissolved in CH2CI2 and purified via flash chromatography (1 :1 Hexanes:EtOAc). Fractions containing the thiourea product were concentrated in vacuo and dried overnight via lyophilization to yield a yellowish-brown solid. Rt3.98 minutes (HP LCMS), LC/MS m/z 596.1 (MH+).
Step 5. Preparation of (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1 -oxo-
2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)- 2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1- carboximidamide
[0327] To a solution of the thiourea in THF (dry, 0.5 M) in a dry vial was added (S)-(+)-2-methylpiperazine (3 eq) and EDC (3 eq). The vial was capped tightly and heated to 80°C for approximately 2 hours. The mixture was then allowed to cool to room temperature and concentrated in vacuo. The reaction mixture was dissolved in DMSO along with TFA (1 eq) and purified by prep HPLC. The pure fractions were collected, frozen, and dried via lyopholization to give the product as a white solid. Rt 9.57 minutes, LC/MS m/z 596.3 (MH+).
[0328] Examples 3-16 were prepared using the procedures described for 1 and 2. Example 3
[0329] (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-3-oxo-2,3-dihydro-1 H- isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yl]piperazine-1 -carboximidamide
[0330] Synthesized from 2-(2,4-dichlorophenyl)ethanamine. Rt 8.72 minutes, LC/MS m/z 582.5 (MH+).
Example 4
[0331] (3S)-N-[2-(2,4-dichlorobenzyl)-1 ,3-dioxo-2,3-dihydro-1 H-isoindol-
5-yl]-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yl]piperazine-1 -carboximidamide
[0332] Synthesized from 1-(2,4-dichlorophenyl)methanamine. Rt 8.72 minutes, LC/MS m/z 582.5 (MH+).
Example 5
[0333] (3S)-N-{2-[(1 S)-1 -benzyl-2-hydroxyethyl]-1 ,3-dioxo-2,3-dihydro-
I H-isoindoI-δ-ylJ-S-methyl-N'-KIS^S.SS.δR^.e.e-trimethylbicyclotS.l .ljhept- 3-yI]piperazine-1 -carboximidamide
[0334] Synthesized from L-phenylalaninol. Rt 7.56 minutes, LC/MS m/z
558.7 (MH+).
Example 6
[0335] (3S)-N-{2-[(1 R)-1 -benzyl-2-hydroxyethyl]-1 ,3-dioxo-2,3-dihydro- 1 H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept- 3-yl]piperazine-1 -carboximidamide
[0336] Synthesized from D-phenylalaninol. Rt 7.52 minutes, LC/MS m/z
558.7 (MH+). Example 7
[0337] (3S)-N-{2-[2-(2-fluoro-4-methylphenyl)ethyl]-1-oxo-2,3-dihydro-
1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept- 3-yl]piperazine-1-carboximidamide
[0338] Synthesized from 2-(3-fluoro-5-methylphenyl)ethanamine. Rt 7.8 minutes, LC/MS m/z 546.2 (MH+).
Example 8
[0339] (3S)-N-{2-[(1S)-1-(2,4-dichlorobenzyl)-2-hydroxyethyl]-1 ,3-dioxo-
2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1 -carboximidamide
[0340] Synthesized from L-2,4-dichlorophenylalaninol, obtained in one step from the reduction of L-2,4-dichlorophenylalanine (see, for example, JOC 2000, 65 , 5037-5042). Rt 8.46 minutes, LC/MS m/z 626.2 (MH+).
Example 9
[0341] (3S)-N-{2-[(1S)-1-(2,4-dichlorobenzyl)-2-hydroxyethyl]-1 -oxo-2,3- dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1 -carboximidamide
[0342] Synthesized from L-2,4-dichlorophenylalaninol, obtained in one step from the reduction of L-2,4-dichlorophenylalanine (see, for example, JOC 2000, 65 , 5037-5042). Rt 7.71 minutes, LC/MS m/z 612.2 (MH+).
Example 10
[0343] (3S)-N-{2-[2-(2-fluoro-4-methoxyphenyl)ethyl]-1 ,3-dioxo-2,3- dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1 ]hept-3-yl]piperazine-1 -carboximidamide [0344] Synthesized from 2-(2-fluoro-4-methoxyphenyl)ethanamine. Rt
8.4 minutes, LC/MS m/z 576.2 (MH+).
Example 11
[0345] (3S)-N-{2-[2-(2,4-difluorophenyl)ethyl]-1 ,3-dioxo-2,3-dihydro-1 H- isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yl]piperazine-1 -carboximidamide
[0346] Synthesized from 2-(2,4-difluorophenyl)ethanamine. Rt 8.53 minutes, LC/MS m/z 564.2 (MH+).
Example 12
[0347] (3S)-N-{2-[2-(2,4-dimethoxyphenyl)ethyl]-1 ,3-dioxo-2,3-dihydro- 1 H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept- 3-yl]piperazine-1 -carboximidamide
[0348] Synthesized from 2-(2,4-dimethoxyphenyl)ethanamine. Rt 8.51 minutes, LC/MS m/z 588.3 (MH+).
Example 13
[0349] (3S)-N-{2-[2-(2,4-dimethylphenyl)ethyl]-1 ,3-dioxo-2,3-dihydro-1 H- isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yl]piperazine-1 -carboximidamide
[0350] Synthesized from 2-(2,4-dimethylphenyl)ethanamine. Rt 9.43 minutes, LC/MS m/z 556.2 (MH+).
Example 14
[0351] (3S)-N-{2-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-
1 ,3-dioxo-2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1 -carboximidamide [0352] Synthesized from (1S,2S)-(+)-2-amino-1-phenyl-1 ,3-propanediol.
Rt 6.68 minutes, LC/MS m/z 574.3 (MH+).
Example 15
[0353] (3S)-N-{2-[(1 R,2R)-2-hydroxy-1 -(hydroxymethyl)-2-phenylethyl]-
1 ,3-dioxo-2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1 ]hept-3-yl]piperazine-1 -carboximidamide
[0354] Synthesized from (1 R,2R)-(-)-2-amino-1-phenyl-1 ,3-propanediol.
Rt 6.64 minutes, LC/MS m/z 574.3 (MH+).
Example 16
[0355] (3S)-N-{2-[(1 S,2R)-2-hydroxy-1 -(hydroxymethyl)-2-phenylethyl]- 1 ,3-dioxo-2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1 ]hept-3-yl]piperazine-1 -carboximidamide
[0356] Synthesized from (1 R,2S)-(+)-2-amino-1-phenyl-1 ,3-propanediol.
Rt 6.63 minutes, LC/MS m/z 574.3 (MH+).
Example 17
[0357] (3S)-N-{2-[2-(2-fluoro-4-methoxyphenyl)ethyl]-1 -oxo-2,3-dihydro-
1 H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept- 3-yl]piperazine-1 -carboximidamide
[0358] Synthesized from 2-(2-fluoro-4-methoxyphenyl)ethanamine. Rt
7.42 minutes, LC/MS m/z 562 (MH+).
Example 18
[0359] (3S)-N-{2-[2-(2,4-difluorophenyl)ethyl]-1-oxo-2,3-dihydro-1 H- isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yl]piperazine-1 -carboximidamide [0360] Synthesized from 2-(2,4-difluorophenyl)ethanamine. Rt 7.5 minutes, LC/MS m/z 550 (MH+).
Example 19
[0361] (3S)-N-{2-[2-(2,4-difluorophenyl)ethyl]-3-oxo-2,3-dihydro-1H- isoindol-5-yl}-3-methyl-N,-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yljpiperazine-1 -carboximidamide
[0362] Synthesized from 2-(2,4-difluorophenyl)ethanamine. Rt 7.82 minutes, LC/MS m/z 550 (MH+).
Example 20
[0363] (3S)-N-{2-[2-(2,4-dimethylphenyl)ethyl]-1 ~oxo-2,3-dihydro-1 H-, lsoindol^y1}-3-methyl-N4(1S,2S,3S,5R)-2f6,6-trimethylbi<^o[3.1.1]hept-3- yl]piperazine-1 -carboximidamide
[0364] Synthesized from 2-(2,4-dimethylphenyl)ethanamine. Rt
8.21minutes, LC/MS m/z 542.1 (MH+).
Example 21
[0365] (3S)-N-{2-[2-(2,4-dimethylphenyl)ethyl]-3-oxo-2,3-dihydro-1 H- isoindol-5-yl}-3-methyl-N,-[(1S,2S,3S,5R)-2,6,6-trimethy)bicyclo[3.1.1]hept-3- yl]piperazine-1 -carboximidamide
[0366] Synthesized from 2~(2,4-dimethylphenyl)ethanamine. Rt 8.5 minutes, LC/MS /z 542.1 (MH+).
Example 22
[0367] (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1 -oxo-1 ,2,3,4- tetrahydroisoquinolin-6-yl}-3-methyl-N'-[(1S,2S,5R)-2,6,6- trimethylbicyclo[3.1.1 ]hept-3-yl]piperazine-1 -carboximidamide [0368] 6-nitroisochroman-1-one was treated with the dimethylaluminum amide prepared from 2-(2,4-dichlorophenyl)ethanamine, and the product obtained was cyclized using Mitsunobu conditions ( as in Ian. Bell et al, Tetrahedron. Lett. (2000), 41, 1141-1145). The nitro group was then reduced, and the amine was converted to the substituted guanidine (as in steps 2-5 of Example 2 above) to give the title compound. Rt 9.06 minutes, LC/MS m/z 596.1 (MH+).
Example 23
[0369] (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1 H-benzimidazol-5-yl}-3- methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1- carboximidamide
[0370] 2,4-dichlorophenyl propionic acid (1.0 eq) was mixed with 4-nitro-
1 ,2-phenylenediamine (1.1 eq) and EDC (1.5 eq) in THF at room temperature for 8 hours. The solution was diluted with ethyl acetate and washed with water (3 x). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. The product was then subjected to refluxing glacial acetic acid for 30 minutes. After removal of the acetic acid in vacuo, the residue was free-based with sodium carbonate. The resulting compound was then subjected to the hydrogenation and guanidino functionalization conditions described in Example 2 above (steps 2, 3, 4, and 5) to give the desired product. Rt 7.08 minutes, LC/MS m/z 567.2 (MH+).
[0371] Examples 24 and 25 can be prepared using the procedures described for Example 23.
Example 24
[0372] (3S)-N-{2-[2-(2,4-dimethylphenyl)ethyl]-1 H-benzimidazol-6-yl}-3- methyl-N'-[(1 S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1- carboximidamide [0373] Synthesized from 3-(2,4-dimethylphenyl)propanoic acid. Rt 6.93 minutes, LC/MS m/z 527.3 (MH+).
Example 25
[0374] (3S)-N-{2-[2-(2-chloro-4-fluorophenyl)ethyl]-1 H-benzimidazol-6- yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine- 1 -carboximidamide
[0375] Synthesized from 3-(2-chloro-4-fluorophenyl)propanoic acid. Rt
6.54 minutes, LC/MS m/z 551.4 (MH+).
[0376] In addition to the synthesis described above, many of the synthetic transformations presented in U.S. Provisional Application No. 60/245,579 are relevant to the synthesis of the compounds of the present invention. Thus, U.S. Provisional Application No. 60/245,579, filed November 6, 2000 is hereby incorporated by reference in its entirety.
In Vitro Data
[0377] EC50 values of test compounds were determined by treating cells expressing MC4-R with test compound and lysing the cells and measuring intercellular cAMP concentration with an Amersham-Pharmacia RPA-559 cAMP Scintillation Proximity Assay (SPA) kit. The following compounds were synthesized and tested according to this assay. The following compounds are merely illustrative and should not be construed as limiting of the instant invention. Compounds having an in vitro potency (as measured by EC50 value) of less than 3 μM include:
[0378] (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1 -oxo-2,3-dihydro-1 H- isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yl]piperazine-1 -carboximidamide; (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1 -oxo- 2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1 ]hept-3-yI]piperazine-1 -carboximidamide; (3S)-N-{2-[2- (2,4-dichlorophenyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'- [(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1- carboximidamide; (3S)-N-[2-(2,4-dichlorobenzyl)-1 ,3-dioxo-2,3-dihydro-1 H- isoindol-5-yl]-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yl]piperazine-1 -carboximidamide; (3S)-N-{2-[(1 S)-1 -benzyl-2-hydroxyethyl]-1 ,3- dioxo-2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1 -carboximidamide; (3S)-N-{2-[(1 R)- 1 -benzyl-2-hydroxyethyl]-1 ,3-dioxo-2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'- [(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1- carboximidamide; (3S)-N-{2-[2-(2-fluoro-4-methylphenyl)ethyl]-1-oxo-2,3- dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1 -carboximidamide; (3S)-N-{2-[(1S)- 1 -(2,4-dichlorobenzyl)-2-hydroxyethyl]-1 ,3-dioxo-2,3-dihydro-1 H-isoindol-5-yl}- S-methyl-N'-KIS^S.SS.δR^.e.e-trimethylbicycIop.l .ljhept-S-yljpiperazine-l- carboximidamide; (3S)-N-{2-[2-(2-fluoro-4-methoxyphenyl)ethyl]-1 ,3-dioxo-2,3- dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1 -carboximidamide; (3S)-N-{2-[2- (2,4-difluorophenyl)ethyl]-1 ,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'- [(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1- carboximidamide; (3S)-N-{2-[2-(2,4-dimethoxyphenyl)ethyl]-1 ,3-dioxo-2,3- dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1 -carboximidamide; (3S)-N-{2-[2- (2,4-dimethyIphenyl)ethyl]-1 ,3-dioxo-2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'- [(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1- carboximidamide; (3S)-N-{2-[(1 S,2S)-2-hydroxy-1 -(hydroxymethyl)-2- phenylethyl]-1 ,3-dioxo-2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'- [(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1- carboximidamide; (3S)-N-{2-[(1 R,2R)-2-hydroxy-1 -(hydroxymethyl)-2- phenylethyl]-1 ,3-dioxo-2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'- [(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1- carboximidamide; (3S)-N-{2-[(1 S,2R)-2-hydroxy-1-(hydroxymethyl)-2- phenylethyl]-1 ,3-dioxo-2,3-dihydro-1 H-isoindol-5-yI}-3-methyl-N'- [(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1- carboximidamide; (3S)-N-{2-[2-(2-fluoro-4-methoxyphenyl)ethyl]-1-oxo-2,3- dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1 -carboximidamide; (3S)-N-{2-[2- (2,4-difluorophenyl)ethyl3-1-oxo-2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'- [(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1- carboximidamide; (3S)-N-{2-[2-(2,4-difluorophenyl)ethyl]-3-oxo-2,3-dihydro-1 H- isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yl]piperazine-1 -carboximidamide; (3S)-N-{2-[2-(2,4-dimethylphenyl)ethyl]-1 - oxo-2,3-dihydro-1 H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1 -carboximidamide; (3S)-N-{2-[2- (2,4-dimethylphenyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N,- [(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1- carboximidamide; (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1 H-benzimidazol-5- yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine- 1 -carboximidamide; (3S)-N-{2-[2-(2,4-dimethylphenyl)ethyl]-1 H-benzimidazol-6- yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine- 1 -carboximidamide; (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1-oxo-1 ,2,3,4- tetrahydroisoquinolin-6-yl}-3-methyl-N'-[(1 S,2S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1 -carboximidamide; (3S)-N-{2-[(1 S)- 1 -(2,4-dichlorobenzyl)-2-hydroxyethyl]-1 -oxo-2,3-dihydro-1 H-isoindol-5-yl}-3- methyl-N'-[(1 S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-1- piperazinecarboximidamide; and (3S)-N-{2-[2-(2-chloro-4-fluorophenyl)ethyl]- 1 H-benzimidazol-6-yl}-3-methyl-N'-[(1 S,2S,3S,5R)-2,6,6- . trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1 -carboximidamide.
In Vivo Studies of MC4-R Agonists on Energy Intake, Body Weight,
Hyperinsulinemia, and Glucose Levels.
[0379] In vivo studies are conducted to observe the effect of MCR-4 agonists on energy intake, body weight, hyperinsulinemia, and glucose levels. All studies are conducted with male 9-10 week old ob/ob mice which display early onset of obesity, insulin resistance and diabetes due to leptin deficiency. iice are acclimated in the facility for 1 week before studies and are caged idividually. Vehicle-treated (control) and drug treated mice studies are always un in parallel. In multi-day studies, mice (8-15 per group) are monitored for baseline body weight, fasting levels of glucose, insulin, blood lipids and energy expenditure and then are injected twice daily (9 a.m. and 5 p.m.) with 3mg/kg of an MC4-R agonist according to the invention for 2-4 weeks. Body weight as well as food and water intake are monitored daily. Animals are fasted overnight for measurements of fasting levels of glucose, insulin, and lipids once a week until the end of the study. Energy expenditure (resting metabolic rate, i.e., O2 consumption and CO2 production) are monitored in air tight chambers at the end of the study on fed animals. O2 consumption and CO2 production are measured using Oxymax systems (Columbus Instruments). Oral glucose tolerance test (OGTT - a routine test for diabetes and glucose intolerance) is performed on overnight fasted mice at the end of the study. Blood glucose and oral glucose tolerance are measured using a glucose monitor (Onetouch sold by Lifescan). Free fatty acids are measured using an nonesterfifed free fatty acids enzymatic assay (Waco Chemicals). Serum Insulin levels are measured by immunoassay (Alpco).
[0380] The results of the above studies show that a significant reduction in food intake occurs in those mice treated IP with the compounds of the present invention. The results also show that mice treated with the compounds of the present invention show a significant body weight reduction compared to mice not treated with the compounds of the present invention. Vehicle treated mice show an increase in blood glucose consistent with the rapid progression of diabetes in this mouse strain, whereas the onset of diabetes is slowed down in mice treated with the compounds of the present invention. Oral glucose tolerance tests are performed. Orally administered glucose quickly elevates blood glucose similar to after eating a meal. Vehicle treated mice show an elevated response to glucose consistent with their diabetic state, whereas mice β ted with the compounds of the present invention show a very much ^H glucose disposal. Mice are fasted overnight and free fatty acid levels are measured the following morning. Vehicle treated mice show elevated free fatty acid levels consistent with their obese state, whereas mice treated with the compounds of the present invention show a dramatic 50% decrease. Serum insulin levels are measured one hour after single IP dosing of compounds of the present invention in overnight fasted ob/ob mice. Mice treated with the compounds of the present invention show a dose dependent decrease relative to vehicle.

Claims

CLAIMSWhat is claimed is:
1. A compound of formula I
wherein
X and Y are independently selected from the group consisting of
CH2, N, NR9, C=O, C=S, S=O, SO2, S, O, (CR6R7)n, C(=OHCR6R7)n, and C(=S)-(CR6R7)n;
n is 1 , 2, or 3;
W is selected from the group consisting of
L is selected from the group consisting of N, O, S, S=O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond;
Z1, Z2, and Z3 are independently selected from the group consisting of CR8 and N;
R1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups; R2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
R3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R3 may join together to form a ring containing at least two N atoms;
R4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R4 may join together to form a ring containing at least two N atoms;
R5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R4 and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R3 and R5 may join together to form a ring containing at least two N atoms;
R6 and R7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
R8 is independently selected from the group consisting of H, CI, I, F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; R9 and R10 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups; and
prodrugs thereof, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
A compound of formula II
wherein
A is selected from the group consisting of C or CH;
X and Y are independently selected from the group consisting of CH2, N, C=O, C=S, (CR6R7)n, S=O, SO2, O, NR9, S, C(=O)-(CR6R7)n, and C(=S)-(CR6R7)n;
n is 1 ,
2, or 3;
W is selected from the group consisting of
Z1, Z2, and Z3 are independently selected from the group consisting of CR8 and N; L is selected from the group consisting of N, O, S, S=O, SO2,
C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond;
R1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
R2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
R3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R3 may join together to form a ring containing at least two N atoms;
R4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl,: arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R4 may join together to form a ring containing at least two N atoms;
R5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R4 and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R3 and R5 may join together to form a ring containing at least two N atoms;
R6 and R7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; R8 is independently selected from the group consisting of H, CI, I,
F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
R9 and R10 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups; and
prodrugs thereof, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
3. A compound of formula
wherein
X and Y are independently selected from the group consisting of CH2, N, C=O, NR9, C=S, S=O, SO2) O, S, (CR6R7)n, C(=O)-(CR6R7)n, and C(=S)-(CR6R7)n;
wherein when X is N, then Y is not N, with the proviso that when X is N, then Y can still be NH;
wherein when Y is N, then X is not N, with the proviso that when Y is N, then X can still be NH;
wherein when X is CH2, then Y is not CH2; wherein when Y is CH2, then X is not CH2;
wherein when X is NH, then Y is not NH;
wherein when Y is NH, then X is not NH;
D is selected from the group consisting of N, and C;
L is selected from the group consisting of N, O, S, S=O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond;
W is selected from the group consisting of
Z1, Z2, and Z3 are independently selected from the group consisting of CR8 and N;
R1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkyialkyl, alkenyl, alkynyl, and alkyl groups;
R2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyialkyl, aryl, and arylalkyl groups;
R3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R3 may join together to form a ring containing at least two N atoms;
R4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R2 and R4 may join together to form a ring containing at least two N atoms;
R5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkyialkyl groups, or R4 and R5, together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R3 and R5 may join together to form a ring containing at least two N atoms;
R6 and R7 may be the same or different, and are each independently selected from the group consisting of H, CI, I, F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
R8 is independently selected from the group consisting of H, CI, I,
F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
R9 and R10 are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkyialkyl, alkylcarbonyl, and arylcarbonyl groups; and
prodrugs thereof, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
4. A composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
5. A method of treating an MC4-R mediated disease, comprising administering to a subject in need thereof, the compound according to claim 1.
6. The method according to claim 5, wherein the disease is obesity or type II diabetes.
7. A composition comprising the compound according to claim 2 and a pharmaceutically acceptable carrier.
8. A method of treating an MC4-R mediated disease, comprising administering to a subject in need thereof, the compound according to claim 2.
9. The method according to claim 8, wherein the disease is obesity or type II diabetes.
EP02719463A 2001-04-09 2002-04-08 Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists Expired - Lifetime EP1385823B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06025693A EP1767525A1 (en) 2001-04-09 2002-04-08 Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
CY20071100208T CY1107442T1 (en) 2001-04-09 2007-02-15 GUANIDINE DERIVATIVES AS MESCELLANTS OF THE MELANOCORTIN-4 (MC4-R) RELATIONSHIP

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28284701P 2001-04-09 2001-04-09
US282847P 2001-04-09
PCT/US2002/010965 WO2002081443A1 (en) 2001-04-09 2002-04-08 Novel guanidino compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06025693A Division EP1767525A1 (en) 2001-04-09 2002-04-08 Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists

Publications (3)

Publication Number Publication Date
EP1385823A1 true EP1385823A1 (en) 2004-02-04
EP1385823A4 EP1385823A4 (en) 2005-02-16
EP1385823B1 EP1385823B1 (en) 2006-12-13

Family

ID=23083379

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06025693A Withdrawn EP1767525A1 (en) 2001-04-09 2002-04-08 Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
EP02719463A Expired - Lifetime EP1385823B1 (en) 2001-04-09 2002-04-08 Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP06025693A Withdrawn EP1767525A1 (en) 2001-04-09 2002-04-08 Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists

Country Status (10)

Country Link
US (4) US7456183B2 (en)
EP (2) EP1767525A1 (en)
JP (1) JP4172541B2 (en)
AT (1) ATE348097T1 (en)
CY (1) CY1107442T1 (en)
DE (1) DE60216747T2 (en)
DK (1) DK1385823T3 (en)
ES (1) ES2278016T3 (en)
PT (1) PT1385823E (en)
WO (1) WO2002081443A1 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3415A1 (en) 2000-08-31 2002-03-07 Chiron Corp GUANIDINOBENZAMIDES AS MC4-R AGONISTS.
EP1767525A1 (en) * 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US20050124652A1 (en) * 2002-02-04 2005-06-09 Rustum Boyce Guanidino compounds
US20030207814A1 (en) * 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
EP1487474A4 (en) * 2002-02-25 2006-11-29 Chiron Corp Intranasal administration of mc4-r agonists
ATE478867T1 (en) 2002-05-23 2010-09-15 Novartis Vaccines & Diagnostic SUBSTITUTED QUINAZOLINONE COMPOUNDS
FR2840302B1 (en) * 2002-06-03 2004-07-16 Aventis Pharma Sa ISOINDOLONE DERIVATIVES, PREPARATION METHOD AND INTERMEDIARY THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
KR20060026011A (en) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 Peptides for use in treating obesity
AU2004249120B2 (en) * 2003-05-23 2008-07-24 Glaxosmithkline Guanidino-substituted quinazolinone compounds as MC4-R agonists
ATE375810T1 (en) * 2003-08-01 2007-11-15 Chugai Pharmaceutical Co Ltd CYANOAMIDE COMPOUNDS AS USEFUL MALONYL-COA DECARBOXYLASE INHIBITORS
US7786145B2 (en) * 2003-08-01 2010-08-31 Chugai Seiyaku Kabushiki Kaisha Cyanoguanidine-based azole compounds useful as malonyl-CoA decarboxylase inhibitors
RU2381233C2 (en) 2003-09-30 2010-02-10 Ново Нордиск А/С Melanocortin receptor agonists
MXPA06005736A (en) * 2003-11-19 2006-12-14 Chiron Corp Quinazolinone compounds with reduced bioaccumulation.
US7531569B2 (en) 2003-12-02 2009-05-12 Sanofi-Aventis Deutschland Gmbh Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives
DE10356717A1 (en) * 2003-12-02 2005-07-07 Aventis Pharma Deutschland Gmbh Process for the preparation of (3-oxo-2,3-dihydro-1H-isoindol-1-yl) -acetylguanidine derivatives
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
UY28945A1 (en) 2004-06-09 2006-01-31 Glaxo Group Ltd PIRROLOPIRIDINE DERIVATIVES
JP4541811B2 (en) 2004-09-13 2010-09-08 キヤノン株式会社 Image processing apparatus, image processing method, and program
BRPI0609268A2 (en) 2005-03-31 2010-03-09 Pfizer Prod Inc cyclopentapyridine and tetrahydroquinoline derivatives
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US7445834B2 (en) * 2005-06-10 2008-11-04 Morin Brian G Polypropylene fiber for reinforcement of matrix materials
US20090324551A1 (en) * 2005-08-22 2009-12-31 The Regents Of The University Of California Office Of Technology Transfer Tlr agonists
JP4723320B2 (en) * 2005-09-05 2011-07-13 明治飼糧株式会社 Blood leptin level increasing agent
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007142755A2 (en) * 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
CA2657640A1 (en) * 2006-07-14 2008-01-24 Pfizer Products Inc. Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
PL2125007T3 (en) 2007-02-07 2014-07-31 Univ California Conjugates of synthetic tlr agonists and uses therefor
BRPI0907907A2 (en) * 2008-02-07 2015-07-28 Univ California Method to inhibit or treat superficial bladder cancer in a mammal, and use of a tlr agonist 7
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
JP5514831B2 (en) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション Substituted bicyclic amines for the treatment of diabetes
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US8729088B2 (en) * 2009-02-11 2014-05-20 The Regents Of The University Of California Toll-like receptor modulators and treatment of diseases
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
BR112012021231A2 (en) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh method for enhancing plant yield, plant, construct, use of a construct, method for producing a transgenic plant, collectable parts of a plant, products derived from a plant, use of a nucleic acid and method for producing a product
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
EP2563764B1 (en) 2010-04-26 2015-02-25 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
CA2797315C (en) 2010-04-30 2018-09-11 Telormedix Sa Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
WO2011143057A1 (en) 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
SG10202010119TA (en) 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
WO2014046950A1 (en) 2012-09-24 2014-03-27 Enable Injections, Llc Medication vial and injector assemblies and methods of use
CN103159667B (en) * 2013-03-15 2015-04-01 四川大学 6-guanidyl-2H-isoindole compound as well as preparation method and application thereof
DK3010568T3 (en) 2013-06-18 2019-05-06 Enable Injections Inc Device for transfer with vial and injection
PL3102576T3 (en) 2014-02-03 2019-12-31 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ror-gamma
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
UA118989C2 (en) 2014-10-14 2019-04-10 Вітае Фармасьютікалс, Інк. Dihydropyrrolopyridine inhibitors of ror-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
CN108463458B (en) 2015-11-20 2022-02-01 生命医药有限责任公司 Modulators of ROR-gamma
TWI757266B (en) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 Modulators of ror-gamma
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of ror gamma
WO2019023207A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of rorϒ
AU2019255310B2 (en) 2018-04-18 2022-11-24 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010842A2 (en) * 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177218A (en) * 1962-01-17 1965-04-06 Monsanto Chemicals Methylene-bis(2-guanidino-4-methylquinazoline)
DE2623846A1 (en) * 1976-05-28 1977-12-15 Hoechst Ag 4-QUINAZOLINYL GUANIDINE AND THE METHOD OF MANUFACTURING IT
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
EP0059597B1 (en) * 1981-02-27 1986-04-23 Imperial Chemical Industries Plc Guanidino-substituted heterocyclic derivatives having histamine h-2 antagonist activity
EP0067508B1 (en) * 1981-05-18 1985-10-30 Imperial Chemical Industries Plc Amidine derivatives
JPS6229566A (en) 1985-07-30 1987-02-07 Taiyo Yakuhin Kogyo Kk Novel guanidinomthylbenzoic acid derivative
DE3614000A1 (en) * 1986-04-25 1987-10-29 Boehringer Mannheim Gmbh NEW ISOCHINOLINDIONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4948901A (en) * 1988-05-24 1990-08-14 Pfizer Inc. Benzamide protease inhibitors
US4874864A (en) * 1988-05-24 1989-10-17 Pfizer Inc. Benzamide protease inhibitors
US4948891A (en) * 1988-05-24 1990-08-14 Pfizer Inc. Benzamide protease inhibitors
US5055479A (en) 1988-06-16 1991-10-08 Sankyo Company, Limited Method of treating cachexia
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
GB8926512D0 (en) 1989-11-23 1990-01-10 Pfizer Ltd Therapeutic agents
CA2032420A1 (en) * 1989-12-22 1991-06-23 Akira Okuyama Guanidinobenzene derivatives
US5124328A (en) 1990-10-11 1992-06-23 Merck & Co., Inc. Morpholine derivatives compositions and use
ES2132393T3 (en) 1993-03-23 1999-08-16 Astra Ab GUANIDINE DERIVATIVES USEFUL IN THERAPEUTICS.
US5807885A (en) * 1993-08-12 1998-09-15 Astra Aktiebolag Amidine derivatives with nitric oxide synthetase activities
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5599984A (en) * 1994-01-21 1997-02-04 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
AU704972B2 (en) 1994-08-04 1999-05-13 H. Lundbeck A/S Novel benzimidazole derivatives
US5637439A (en) 1994-11-07 1997-06-10 Mitsubishi Paper Mills Ltd. Photographic silver halide photosensitive material and method for developing the same
AU4534596A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
DE19544687A1 (en) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Amino acid derivatives, medicaments containing these compounds and processes for their preparation
DE19544685A1 (en) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Amino acid derivatives, medicaments containing these compounds and processes for their preparation
ATE212978T1 (en) 1996-03-29 2002-02-15 Searle & Co PARA-SUBSTITUTED PHENYLPROPANE ACID DERIVATIVES AS INTEGRIN ANTAGONISTS
ZA973850B (en) 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5766877A (en) * 1996-05-10 1998-06-16 Amgen Inc. Genes encoding art, an agouti-related transcript
US6127343A (en) * 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
ATE218859T1 (en) 1996-08-23 2002-06-15 Agouron Pharma LIGANDS OF NEUROPEPTIDE Y
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
AU4772497A (en) * 1996-10-31 1998-05-22 Novo Nordisk A/S Constrained somatostatin agonists and antagonists
RU2194700C2 (en) * 1996-11-25 2002-12-20 Дзе Проктер Энд Гэмбл Компани Guanidyl heterocyclic compounds using as agonists of alpha-2 adrenoceptors
US5866579A (en) 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
WO1997041119A1 (en) 1997-05-02 1997-11-06 Dr. Reddy's Research Foundation Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
JP2001524478A (en) 1997-11-24 2001-12-04 ザ プロクター アンド ギャンブル カンパニー 5- (2-imidazolinylamino) -benzimidazole derivatives, their preparation and their use as alpha adrenergic receptor agonists with improved metabolic stability
CA2334551A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
DE19831710A1 (en) 1998-07-15 2000-01-20 Merck Patent Gmbh New diacyl-hydrazine derivatives, are integrin inhibitors useful for treating e.g. thrombosis, cardiac infarction, tumors, osteoporosis, inflammation or infection
FR2784678B1 (en) 1998-09-23 2002-11-29 Sod Conseils Rech Applic NOVEL N- (IMINOMETHYL) AMINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2000047207A1 (en) * 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
JP2003505435A (en) 1999-06-04 2003-02-12 メルク エンド カムパニー インコーポレーテッド Substituted piperidines as melanocortin-4 receptor gonists
US20040224958A1 (en) 2000-01-27 2004-11-11 Booth Richard John Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
MXPA02007289A (en) 2000-01-28 2003-09-22 Melacure Therapeutics Ab Novel melanocortin receptor agonists and antagonists.
WO2001055107A2 (en) 2000-01-28 2001-08-02 Melacure Therapeutics Ab Aromatic amines and amides acting on the melanocortin receptors
WO2001070708A1 (en) 2000-03-23 2001-09-27 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
CA2403631A1 (en) 2000-03-23 2001-09-27 Brenda L. Palucki Spiropiperidine derivatives as melanocortin receptor agonists
JP2001302667A (en) 2000-04-28 2001-10-31 Bayer Ag Imidazopyrimidine derivative and triazolopyrimidine derivative
DZ3415A1 (en) * 2000-08-31 2002-03-07 Chiron Corp GUANIDINOBENZAMIDES AS MC4-R AGONISTS.
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
EP1767525A1 (en) * 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
ATE478867T1 (en) 2002-05-23 2010-09-15 Novartis Vaccines & Diagnostic SUBSTITUTED QUINAZOLINONE COMPOUNDS
US6638297B1 (en) * 2002-05-30 2003-10-28 Ethicon Endo-Surgery, Inc. Surgical staple

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010842A2 (en) * 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO02081443A1 *

Also Published As

Publication number Publication date
CY1107442T1 (en) 2012-12-19
DK1385823T3 (en) 2007-03-26
JP2004535378A (en) 2004-11-25
DE60216747D1 (en) 2007-01-25
DE60216747T2 (en) 2007-10-04
US20050038027A1 (en) 2005-02-17
EP1767525A1 (en) 2007-03-28
US20040248895A1 (en) 2004-12-09
EP1385823A4 (en) 2005-02-16
US7456183B2 (en) 2008-11-25
WO2002081443A1 (en) 2002-10-17
JP4172541B2 (en) 2008-10-29
US20040024211A1 (en) 2004-02-05
US20020193595A1 (en) 2002-12-19
US7189727B2 (en) 2007-03-13
US6960582B2 (en) 2005-11-01
ATE348097T1 (en) 2007-01-15
US6716840B2 (en) 2004-04-06
EP1385823B1 (en) 2006-12-13
PT1385823E (en) 2007-01-31
ES2278016T3 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
US6716840B2 (en) Guanidino compounds
CA2420694C (en) Guanidinobenzamides as mc4-r agonists
EP1551834B1 (en) Substituted quinazolinone compounds
AU2001288604A2 (en) Guanidinobenzamides as MC4-R agonists
AU2001288604A1 (en) Guanidinobenzamides as MC4-R agonists
US20030195187A1 (en) Guanidino compounds
WO2005051391A1 (en) Quinazolinone compounds with reduced bioaccumulation
US20050124652A1 (en) Guanidino compounds
ZA200301544B (en) Guanidinobenzamides as MC4-R agonists.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050107

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/425 B

Ipc: 7C 07D 235/28 B

Ipc: 7C 07D 217/22 B

Ipc: 7C 07D 235/08 B

Ipc: 7C 07D 235/10 B

Ipc: 7C 07D 209/48 B

Ipc: 7C 07D 209/02 A

Ipc: 7C 07D 235/24 B

Ipc: 7C 07D 403/02 B

Ipc: 7C 07D 209/44 B

Ipc: 7C 07D 277/62 B

Ipc: 7A 61K 31/47 B

Ipc: 7C 07D 217/24 B

Ipc: 7C 07D 209/46 B

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: GUANIDINO COMPOUNDS AS MELANOCORTIN-4 RECEPTOR (MC4-R) AGONISTS

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

REF Corresponds to:

Ref document number: 60216747

Country of ref document: DE

Date of ref document: 20070125

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20070111

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC., US

Effective date: 20070117

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Effective date: 20070124

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20070400820

Country of ref document: GR

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2278016

Country of ref document: ES

Kind code of ref document: T3

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070914

REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

BECN Be: change of holder's name

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS INC.

Effective date: 20061213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070408

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20090415

Year of fee payment: 8

Ref country code: IE

Payment date: 20090420

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20090416

Year of fee payment: 8

Ref country code: LU

Payment date: 20090424

Year of fee payment: 8

Ref country code: SE

Payment date: 20090407

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20090330

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20090323

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20100319

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100325

Year of fee payment: 9

Ref country code: TR

Payment date: 20100312

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20100505

Year of fee payment: 9

Ref country code: FR

Payment date: 20100521

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20100413

Year of fee payment: 9

Ref country code: DE

Payment date: 20100430

Year of fee payment: 9

Ref country code: IT

Payment date: 20100420

Year of fee payment: 9

Ref country code: NL

Payment date: 20100402

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20100423

Year of fee payment: 9

Ref country code: CH

Payment date: 20100414

Year of fee payment: 9

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20100317

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100408

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100408

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Free format text: NOVARTIS VACCINES AND DIAGNOSTICS, INC.#4560 HORTON STREET#EMERYVILLE, CA 94608 (US) -TRANSFER TO- NOVARTIS VACCINES AND DIAGNOSTICS, INC.#4560 HORTON STREET#EMERYVILLE, CA 94608 (US)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100503

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20111010

BERE Be: lapsed

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS INC.

Effective date: 20110430

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20111101

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110408

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 348097

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110408

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20070400820

Country of ref document: GR

Effective date: 20111102

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20111230

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111101

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111101

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111010

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110502

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111102

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110408

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110408

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110408

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60216747

Country of ref document: DE

Effective date: 20111101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100408

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100409

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20131030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110409

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110408